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ABSTRACT 
 
Development of a new, or candidate, therapeutic drug is a challenging process that must 
ensure that favorable target selectivity, potency, pharmacokinetics, and pharmacodynamics, as 
well as lack of toxicity, all fall within the therapeutic window. During the hit-optimization 
stage, the focus shifts toward optimizing potency and target selectivity. Fragment-based 
methods have recently been developed to the point where they represent a promising strategy 
in drug discovery, where a variety of biophysical techniques may be employed for fragment 
library screening and characterizing hit-fragments. Hit-fragments deduced from fragment-
based screenings typically have ligand efficiencies (LE) exceeding those of average HTS-hits. 
Structure data on the complexes formed by fragment-target-protein structures yield a much-
better starting point for hit optimization and lead discovery. 
 
This dissertation presents two fragment-screening studies. Under the first, surface-plasmon-
resonance (SPR) analyses and biochemical assays at high compound concentrations (HCA) 
were employed in primary screenings of protein-kinase A (PKA) that were followed by X-ray 
crystallographic determinations of the structures of the PKA-fragments involved. The aim of 
that study was testing the characteristics, outcomes, and limits of both SPR and HCA as 
fragment-screening methods, as well as estimating hit rates that could be confirmed by X-ray 
crystallographic analyses. Under the second, in-house, biochemical-assay data were used for 
selecting the fragment-like inhibitors of PKA to be subjected to X-ray crystallographic 
structure determinations. The biochemical-assay data involved were taken from screening 
campaigns, such as high-throughput screenings (HTS), or other, available, in-house, 
biochemical-assay runs. The goal there was estimating the extent to which existing HTS-data 
might be utilized for obtaining three-dimensional, fragment-target, protein structure data, 
without need for conducting any additional fragment-screening runs. 
 
Following screening a library of 257 fragment-like compounds using SPR and HCA, a total of 
26 hit-fragments were chosen for X-ray structure determinations, which yielded the structures 
of nine fragment-PKA-structures. Under the second approach, 67 fragments exhibiting > 50 % 
inhibitions taken from the available, in-house, biochemical-assay data were selected for 
structure determinations, which yielded the structures of 21 fragment-PKA-complexes. Both 
approaches yielded respectable hit rates and descriptions of the characteristics of numerous 
fragment-protein interactions. The structural information and data on fragment-target-protein 
complexes gained from those two setups might well accelerate the drug-discovery process 
throughout the pharmaceutical industry. 
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 ZUSAMMENFASSUNG 
 
Die Entwicklung eines neuen therapeutischen Arzneimittels ist ein umfassender Prozess. Sie 
schließt umfangreiche Studien von Wirksamkeit, Selektivität, Pharmakokinetik, 
Pharmakodynamik und Toxizitätsbestimmungen ein. Während der Hit-Optimierungsstufe 
liegt der Fokus auf der Optimierung von Bindungsaffinität und Selektivität. Als 
vielversprechende Strategie werden seit kurzem Fragment-basierte Studien als neue Methode 
im Bereich der Wirkstoffidentifizierung angewendet (Fragment Based Drug Discovery - 
FBDD). Dabei kommen eine Vielzahl biophysikalischer Technologien für das sogenannte 
Fragment-Screening und die Charakterisierung von Hit-Fragmenten zum Einsatz. Die im 
Fragment-Screening gefundenen Hit-Moleküle haben in der Regel eine höhere Ligand-
Effizienz (LE) als HTS-hits. Die nachfolgende Aufklärung des Bindungsmodus der Fragment-
Hits im Proteintarget durch Röntgenstrukturanalyse ist essentieller Bestandteil des Fragment-
Screenings. Die Strukturdaten dieser Fragment-Target-Proteinstrukturen gebildet geben einen 
viel besseren Ausgangspunkt für die folgende Hit-Optimierung durch rationales Design. 
 
Die vorliegende Dissertation präsentiert zwei Fragment-basierte Studien zum Screening von 
Protein-Kinase A (PKA) Inhibitoren. Zuerst wurden Oberflächen-Plasmon-Resonanz (Surface 
Plasmon Resonance - SPR) Analysen und biochemische Inhibitionsmessungen bei hohen 
Fragment Konzentrationen (High Concentration Assay - HCA) durchgeführt. Danach erfolgte 
die Strukturbestimmung der PKA-Fragment Komplexe mit Hilfe der Röntgenstrukturanalyse.  
 
Das Ziel dieser Studie war die Prüfung der Kenndaten, Ergebnisse und Grenzen von SPR und 
HCA als Fragment-Screening-Methoden, sowie die Bestätigung der Fragment-hits durch 
Röntgenstrukturanalyse. In der zweiten Studie wurden Daten eines bei Merck etablierten 
biochemischen Assays für die Fragmentwahl herangezogen und ebenfalls die Struktur dieser 
Fragment-PKA Komplexe kristallographisch bestimmt. Die biochemischen Inhibitionsdaten 
werden parallel zu den Screening-Kampagnen, wie z. B. High-Throughput-Screening (HTS) 
und anderen Merck internen Tests erfasst. Ziel war es, zu klären, in welchem Umfang 
bestehende HTS-Daten ohne zusätzliches Fragment Screening für den Erhalt von drei-
dimensionalen Fragment-Target-Protein-Struktur-Daten genutzt werden können. 
 
Es wurde eine Bibliothek von 257 Fragment Molekülen mittels SPR und HCA gescreent. Aus 
den Ergebnissen wurden insgesamt 26 Hit-Fragmente für X-ray Bestimmungen gewählt, 
woraus neun Fragment-PKA-Strukturen gelöst werden konnten. Im zweiten Ansatz wurden 
67 Fragmente für die Röntgenstrukturanalyse ausgewählt, die in den biochemischen 
Inhibitionsmessungen eine mehr als 50%ige Hemmungen der PKA Substrat-Phosphorylierung 
zeigten. Aus diesem Ansatz  ergaben sich 21 Fragment-PKA-Komplex Strukturen. Beide 
Ansätze ergaben beachtliche Trefferquoten und interessante Bindungsmodi der Fragment-
Protein-Interaktionen. Die in dieser Arbeit identifizierten Fragmente und Proteinstukturen 
zeigen den Erfolg Fragment-basierter Methoden in der Wirkstoffforschung. 
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Chapter 1 
INTRODUCTION 
 
 
1.1. FRAGMENT-BASED LEAD DISCOVERY (FBLD) 
The development of new therapeutic drugs requires the maturation of chemical compounds 
possessing attributes that makes them effective medications. Specificity, potency, 
bioavailability, duration of action, and lack of toxicity are some of the parameters that have to 
be considered and optimized in the course of designing drug molecules and that define the 
final characteristics of drug-like compounds. The challenge in preclinical drug discovery 
research is identifying the optimized molecular properties involved. 
 
Screening large collections of compounds is a leading paradigm for identifying new starting 
points for developing drug molecules. Under screening campaigns, large collections of 
molecules are rapidly tested for activity against targets using high-throughput screening 
(HTS) techniques. Compounds identified as hits are characterized and upgraded by 
pharmaceutical chemists in order to arrive at drug-like properties (Jhoti, 2005).  
 
Upgrading compounds listed in screening libraries leads to the development of molecules that 
are characterized as “lead-like.” Lead-like molecules possess a majority of the parameters of 
drug-like compounds, but lack final proof that they are optimal choices. The concepts “lead-
like” and “drug-like” have been developed in order to describe what constitutes good leads for 
drug development, and imply cutoff points in the physicochemical profiles of the compounds 
involved that will limit their complexity, for example, confine their molecular weights to 
values < 400 (Hann and Tudor, 2004) 
 
Recently, there has been increasing interest in a new approach to generation of lead-like 
molecules based on identification of small molecules termed “fragments” (Davies, et al., 
2004). Such fragments have low molecular weights, typically less than 300 Da, and usually 
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contain fewer functional groups (Hartshorn, et al., 2005). Employment of fragments in drug 
development is alternatively referred to as “fragment-based lead discovery (FBLD), 
“fragment-based drug discovery,” (FBDD) or “fragment screening.” 
 
Employment of FBLD has revealed several key factors that are critical in the case of 
fragment-based approaches and distinguish them from other hit-identification techniques. The 
first is a more-efficient probing of the chemical space (Jahnke and Erlanson, 2006). Screening 
collections of smaller molecules allows more efficiently covering the chemical space 
involved, which may be exemplified by comparing a library of fragment molecules with a 
library of molecules that might have come from an HTS-collection program. The theoretical 
total number of prospective fragment molecules composed of twelve or fewer heavy atoms, 
excluding three-member and four-member ring structures, has been estimated to be 107, while 
the total number of prospective drug-like molecules, i.e., molecules composed of thirty or 
fewer heavy atoms, has been estimated to exceed 1060 (Jahnke and Erlanson, 2006). A 
fragment-compound library listing fewer molecules than a library listing molecules obtained 
from an HTS-collection can therefore represents a basis for screening more of the chemical 
space falling within the applicable molecular-weight range. Fig.1 depicts the definitions of 
chemical space employed in HTS and FBLD. 
HTS FBLD
 
Fig. 1. Illustration of the expansion of the chemical space covered under FBLD (Jahnke and Erlanson 
(2006)). The estimated, theoretical drug space covers 1060 molecules (Jahnke and Erlanson, 2006), while the 
theoretical fragment space covers 107 molecules, which leads to a greatly condensed compound collection, or 
library, capable of covering larger portions of the chemical space when working with FBLD-approaches. 
 
The second results from the fact that smaller molecules are better able to adapt their 
interactions to suit conditions in targets’ binding pockets, which leads to fragment binding 
Theoretical “drug space” 
(MWT < 500):  
1060 molecules 
HTS-collections: 
108 molecules 
 
Theoretical “fragment space”
Fragment libraries: 
(MWT < 160):  
103 molecules 107 molecules 
~ 1:104 ~ 1:1052 
Source: Fragment-Based Approaches in Drug Discovery, (2006), Wiley VCH 
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efficiencies per atom, which might also be termed “ligand efficiencies” (LE), that are at least 
equal to those for larger hit-molecules. Fragment LE are defined as their Gibbs free energy, 
∆G, divided by the total number of heavy atoms, i.e., atoms heavier than hydrogen, #HA, that 
they incorporate (Hopkins, 2004), i.e.:  
  
(Eq. 1) 
Application of alternative approaches to screening for drug-target interactions provides 
supplementary data of use in searches for chemical scaffolds. Since fragment molecules have 
properties that differ from those of typical HTS-hits, employing fragments could benefit both 
novelty and downstream intellectual-property rights in conjunction with optimizations of hits 
targeted at arriving at marketable drugs (Albert, et al., 2007). The aim is finding small 
scaffolds that might serve as starting points for synthetic efforts to arrive at compounds other 
than those listed in HTS compound pools. 
 
The emergence of low-affinity fragments as prospective starting points for pharmacological 
optimizations necessitates a re-evaluation of the generally accepted criteria governing 
compounds regarded as screening hits. Even low-affinity compounds might represent viable 
candidates for admission to the relevant chemical space. If a rational hypothesis for 
elaboration of the compounds involved can be formulated, low-affinity fragments might also 
support the discovery of new active drug ingredients. FBLD’s ability to supply that 
information is dictated by the detection limits of the techniques employed, which has been a 
key factor in the development of FBLD-methods. Technical advances and the availability of 
more-sensitive detection systems have allowed development of various methods for 
characterizing a large number of low-affinity interactions. In many cases, the techniques 
involved have been developed in conjunction with fragment-based studies. 
 
In general, the objective of screening campaigns is sifting out numbers of compounds 
covering chemical spaces that will be sufficient for supplying data that may be utilized in 
creating drugs that will be effective against specific targets. The numbers of compounds 
involved must fall within testable ranges for the particular targets and methods employed. 
Numerous examples of fragment libraries have been mentioned in the literature. Although 
they typically cover fewer than 1,000 fragment molecules (Reynolds, et al., 2008), some cover 
several thousand molecules (Jahnke and Erlanson, 2006; Hartshorn, et al., 2005). The 
essential properties of the fragments covered must be accurately known and reliable. High 
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fragment solubility and presence of no more than a few reactive groups represent fragment 
properties of importance when endeavoring to avoid interferences with screening assays, 
thereby minimizing the numbers of false positives and false negatives that arise during 
screening (Jahnke and Erlanson, 2006). Suitable fragment solubilities are thus one of the 
most-important fragment properties (Di and Kerns, 2006). Concentrated stock solutions 
should have solubilities therein falling within the range 10-1 M – 1 M (Ciulli and Abell, 2007). 
The purities and chemical stabilities of fragment molecules are also important. A ”rule of 
three” (RO3) has been derived from analyses of a diverse set of hit-fragments identified as 
such against a range of targets (Congreve, et al., 2003). That study indicated that hit-
fragments appeared to track just a few molecular properties. The RO3 defines the molecular 
weights (MWT) of fragments as less than 300Da, the computed octanol/water partition 
coefficient (clogP) as equal to, or less than, 3, the total number of hydrogen-bond acceptor 
and donors (HBA and HBD, respectively) as equal to, or less than, 3, and the total number of 
rotatable bonds (NROT) as equal to, or less than, 3. It also suggests that the total polar surface 
areas (TPSA) of the individual molecules involved are equal to, or less than, 60 Å2 (cf. Table 
1). Further suggestions for fragment properties of interest have been based on designs for a 
fragment “molecular framework” (Bemis and Murcko, 1996; Bemis and Murcko, 1999; 
Bohacek, et al., 1996). Combinations of ring systems, subring systems, linker atoms, and side 
chains may be utilized for generating complex chemical conformations. Once their patternings 
have been deduced, drug designers may apply them in various ways, for example, to 
designing a fragment-molecule library. Fig.2 depicts a sample design for a molecular 
framework.  
 
Fig.2. Diagramatic representation of a model molecular framework (Bemis and Murcko, 1996). The 
structure framework of a six-member ring has been utilized for forming several, different, six-member, ring 
scaffolds. Employment of various molecular frameworks allows assembling a wide variety of chemical scaffolds 
for use in FBLD-approaches.  
 
Examples of recently developed criteria that have been incorporated into the designs of 
fragment libraries are synthetic tractability, increased scaffold coverage, or the availability of 
close molecular analogs (Schnur, 2008; Gillet, 2008; Jahnke and Erlanson, 2006; Leach, et al., 
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2006). An example of a tractable synthetic chemical group is a fragment having a carboxylic 
acid appendage that might provide a handle for further chemical upgradings in conjunction 
with fragment optimizations (Jahnke and Erlanson, 2006). However, such approaches need to 
be handled with care, since it is likely that tractable chemical groups provide key interactions 
with target proteins that would be removed by chemistry that makes use of their tractability. 
Furthermore, fragments should not contain any reactive chemical groups. Groups or chemical 
scaffolds that randomly react with numerous targets are usually termed “frequent hitters” 
(Roche, et al., 2002) or “bad functional groups” (BFGs). Table 1 lists several selection criteria 
applying to fragment molecules. 
 
Table 1. Fragment-molecule selection criteria. There are several approaches to designing fragment libraries, 
where the “rule of three” (RO3) is commonly employed. Empirical parameters, such as fragment solubilities, 
purities, and chemical stabilities, are collected and evaluated. Certain molecular frameworks may be used. 
Further approaches are usage of chemical handles or targeted libraries for certain protein classes. The parameters 
involved are frequently derived from in-silico/computational approaches, combined with manual inspections. 
 
Rule of Three Experimental Factors Other Factors 
Molecular weight < 300 Da Solubility in stock solutions (10-1M - 1 M) Molecular frameworks  
clogP < 3 Solubility in buffering solutions 
(10-3 M - 10-2 M) 
Exclusion of reactive groups 
HBA < 3 Chemical purity Chemical handles 
HDB < 3 Chemical stability Fragment analogs available 
NROT < 3 Commercial availability A library targeted against a 
specific class of proteins 
TPSA < 60 Å2   
 
Since fragment affinities frequently fall within the µM - mM concentration range, fragment-
screening methodologies must be able to detect fragment binding constants over that 
concentration range. Most detection techniques also require binding-site occupancies of 
> 20 % for reliable identifications of ligand binding (Jahnke and Erlanson, 2006). 
Employment of high fragment concentrations will thus be necessary. Detection of relatively 
weak interactions and high fragment concentrations imposes stringent demands upon 
screening and characterization methods. Experimental methods, such as nuclear magnetic 
resonance (NMR), surface plasmon resonance (SPR), mass spectrometry (MS), biochemical 
assays and protein crystallography, represent screening methods that have been mentioned in 
conjunction with FBLD-applications (Zartler and Shapiro, 2005). Technical progress in those 
areas has led to their successful employment in FBLD-applications, which, in turn, has led to 
FBLD acquiring greater acceptance as a further tool of use in early-stage, preclinical, drug 
discovery. 
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In most cases, the characteristics of the fragment-target interactions involved will fail to meet 
the criteria demanded of lead-like or drug-like compounds. Chemical synthesis is then applied 
in order to manipulate and upgrade fragment properties in order to yield sustainable series of 
chemical leads (Leach, et al., 2006). Fragments may be viewed as building blocks that may be 
combined or elaborated on in order to form more-potent, more-attractive, lead compounds. 
Numerous approaches have been applied to the identification and elaboration of fragment 
molecules. Fig.3 presents an example of a workflow chart for a typical fragment-based lead-
discovery project. 
 
Fig.3. Example of a workflow for a fragment-based lead-discovery project. Example diagram of a workflow 
and screening cascade for the case where target structure information is available (Jahnke and Erlanson, 2006). A 
library is designed and an initial screening subsequently detects fragment hits, which is followed by a 
characterization of the hit-fragments involved in order to determine their affinities. X-ray crystallography is then 
applied in order to determine their 3D-binding modes on the target. A decision-making point, where the data 
must be analyzed in order to decide on the next approaches, such as pharmacological studies, to be employed 
then arises. For example, ligand efficiencies (LE) might be computed and analogs of the hits subjected to testing. 
The fragments involved then enter the optimization cycle, where x-ray crystallographic analyses, binding-
constant determinations, and pharmacological syntheses are employed in order to optimize molecules and arrive 
at compounds that are more lead-like.  
 
One approach depicted in Fig.3 is searching for molecular analogs to hit-fragments. Mole-
cules that are structurally similar to hit-fragments are identified and tested for activity against 
the target in order to discover molecules having binding affinities better than those of initial 
hits (Carr, et al., 2005). Such minor structure modifications allow arriving at structure-activity 
relationships (SAR) centered on initial fragment hits. The aim there is assessing the latent 
efficiencies of molecular chemical cores, e.g., assembling a pharmacophore. The 
pharmacophore/fragment may then be employed in several ways, e.g., employed in 
computational approaches or synthetic-chemistry approaches.  
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Several common means for utilizing hit-fragments for developing lead molecules are those 
termed “fragment growing,” “fragment merging,” and “fragment linking,” along with the 
employment of fragments in “scaffold hopping.” Fragment growing utilizes the fragments 
involved as starting points, where fragment molecules are modified, or grown, such that they 
pick up more interactions in binding pockets and acquire greater affinities for targets, while 
simultaneously retaining the properties of lead-like or drug-like substances. Available 
structure-activity relaltionships (SAR) may be utilized for designing the stages in fragment-
growing procedures. Fragment linking represents yet another approach, under which 
fragments that bond to distinct zones on binding pockets are detected using protein 
crystallography. The fragments involved are then linked such that their initial binding modes 
are preserved and the affinities of the resultant complexes will be optimized. An extraordinary 
approach to fragment linking, termed “fragment self-assembly,” has been exemplified by the 
use of in-situ chemistry, where two fragments were linked together in a protein-binding 
pocket. A retrosynthetic-fragment approach has been described as utilizing pre-existing lead 
series from the pharmacochemical literature for deriving fragments focused on specific targets 
(Hajduk, 2006). Lead molecules are broken down into their key fragments and regrown in 
order to arrive at new chemical scaffolds that fit into protein-binding sites. Fig.4 illustrates the 
fragment-growing and fragment-linking approaches to fragment optimization. 
 
 
Fig.4. Examples of two approaches to upgrading fragments into lead molecules. (a) Fragment growing, 
where molecule A is detected under a fragment screening and then grown into sub-pocket B on the target. (b) 
Fragment linking, where molecules A and B are detected under a fragment screening and then linked together 
using a chemical-linker’s moiety.  
 
Pharmaceutical companies, biotechnology companies, and university research groups have all 
reported several successful examples of FBLD over the past few years. 
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Table 2 summarizes the progress made by the initial compounds discovered, on their way to 
clinical trials. 
Table 2. Clinical and preclinical candidates derived from fragments (Congreve, et al., 2008). 
Compound Company Target Progress 
LY-517717 Lilly/Protherics FXa Phase 2 
PLX-204 Plexxikon PPAR-agonist Phase 2 
ABT-263 Abbott Bcl-XL Phase 1/2a 
AT9283 Astex Aurora Phase 1/2a 
ABT-518 Abbott MMP-2 and 9 Phase 1 
AT7519 Astex CDKs Phase 1 
PLX-4032 Plexxikon B-RafV600E Phase 1 
SGX523 SGX Pharmaceuticals MET Phase 1 
SNS-314 Sunesis Aurora Phase 1 
NVP-AUY922 Vernalis/Novartis HSP90 Phase 1 
AT9311/LCQ195 Astex/Novartis CDKs preclinical 
AT13148 Astex PKB/Akt preclinical 
AT13387 Astex HSP90 preclinical 
PLX-4720 Plexxikon B-RafV600E preclinical 
RO6266 Roche P38 preclinical 
SGX393 SGX Pharmaceuticals BCR-AblT315I preclinical 
1.2. APPLICATIONS OF FBLD 
FBLD challenges the techniques and methods utilized in current drug-discovery projects. 
Methods, such as NMR, SPR, ITC, and protein crystallography, have been optimized to the 
point where they are robust and meet the requirements for detecting weak fragment-protein 
interactions (Jahnke and Erlanson, 2006). The term “biophysical methods” may be applied to 
grouping those methods that have also gained greater importance in the field of modern drug 
discovery. In this dissertation, surface-plasmon-resonance  (SPR) analyses, enzymatic high 
compound concentration assays (HCA), and protein crystallography have been applied to 
investigations of fragment-protein interactions. 
 
Detection of ligand-protein binding events using SPR-instrumentation has made major strides 
during recent years. Lower signal/noise ratios have allowed detecting molecules whose 
molecular weights fall within the 100-Da – 300-Da range. Technological advances have also 
simplified the handling of large numbers of compounds dissolved in DMSO. SPR-methods 
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have meanwhile been developed to the point where they represent feasible options for 
studying interactions between fragment molecules and target proteins (Lundqvist, 2005).  
 
The SPR-approach utilized in this dissertation immobilizes proteins on the sensor chip’s 
surface and injects fragments in a stream flowing across its surface and employs a method 
termed “direct-binding assay,” under which responses are proportional to the quantities of 
fragments bound to the proteins resident on its surface (Karlsson, et al., 2000; McDonnell, 
2001; Deinum, et al., 2002). Use of SPR in FBLD has been previously reported in various 
studies (Edwards, et al, 2007; Cannon and Myszka, 2002; Geschwinder, et al., 2007; 
Hämälainen, et al., 2008; Boehm, et al., 2000; Metz, et al., 2003; Neumann, et al., 2005; 
Papalia, et al., 2006; Nordin, et al., 2005). SPR can simultaneously provide data on bond 
formation, binding stoichiometry, binding selectivity, and estimated affinities, which has 
made it a method frequently utilized in FBLD (Huber, 2005; Geschwinder, et al., 2007; 
McDonnell, 2001; Deinum, et al., 2002).  
 
Recently, the approach to finding new starting points via screening large compound libraries 
has come to be most widely employed in drug-discovery programs. Most current drug-
discovery programs include assays based on inhibition or stimulation of a biochemi-
cal/enzymatic mechanism of molecular targets. High-throughput methods, such as HTS, are 
utilized for screening libraries covering several hundred thousand compounds for activity 
against the intended targets. HTS-hits usually have binding constants falling in the nM-range 
or low µM-range, while the aim of fragment screening is detecting bonds having binding 
constants extending up to the high-µM-range and mM-range. In order to detect bonding at 
such high affinities, ligand concentrations also must reach such high concentrations. The 
biochemical assays employed in the case of fragments are therefore often termed “high-
concentration biochemical assays” (HCA) or high-concentration screening” (HCS) assays. 
One advantage of HCA fragment assays is that they may be readily employed in a similar 
manner for screenings conducted in conjunction with HTS-campaigns, since the frag-
ment-HCA involved do not require substantial lengths of time for assay development. 
FBLD-efforts that employ HCA-methods are thus subject less throughput limitations (Barker, 
et al., 2006), which may allow relatively rapid pursuit of wider explorations of fragment 
chemical-space diversities and follow-up methods, such as fragment-analog approaches 
(Hesterkamp and Whittaker, 2008; Gribbon and Sewing, 2008).  
 
21 
  
Protein crystallography is utilized for determining the three-dimensional bonding modes of 
fragments on target proteins at the atomic-site level. Knowledge of 3D-binding modes 
facilitates upgrading fragment molecules into lead-like molecules. Recent developments and 
improvements in protein crystallography have led to an optimized protein-crystallography 
workflow and faster determinations of 3D-structures, which has also benefited the 
implementation of protein crystallography as a tool in FBLD (Blundell, 2001; Gill, et al., 
2005; Nienaber, et al., 2000; Sharff and Jhoti, 2003; Hartshorn, et al., 2005). Furthermore, 
protein crystallography has also been used as a lone technique in FBLD-approaches (Blundell, 
2001; Gill, et al., 2005; Nienaber, et al., 2000; Sanders, et al., 2004; Bosch, et al., 2006). 
Protein crystallography has been used to reveal several interesting fragment-compound 
bonding modes and been applied as a research tool for developing drugs for a range of various 
targeted diseases (Erlanson, 2006; Carr, 2007; Norman, 2007; Erlanson, 2004; Howard, et al., 
2006; Frederickson, et al., 2008; Warner, et al., 2006; Hohwy, et al., 2008). The growing 
numbers of therapeutic targets whose crystalline structures have been determined also 
increase the number of prospective applications of protein crystallography to FBLD. 
1.3. PROTEIN KINASES AND PKA 
Approximately 2 % of the genes in the human genome encode for protein kinases (Manning, 
et al., 2002). Those enzymes constitute one of the largest gene families and are crucial to the 
regulation of various cellular processes. Furthermore, those enzymes play an important role in 
cell growth and cell-signaling transduction (Taylor, et al., 2004). The primary function of 
protein kinases is catalyzing the phosphoryl transfer of the γ-phosphate group on adenosine 
triphosphate (ATP) to the hydroxyl group of a recipient substrate, which occurs as a response, 
following receipt of a signal from an upstream, signaling protein. 
 
Protein phosphatases are the antagonists of protein kinases and counteract protein kinases by 
detaching their appended phosphate groups and terminating transmission of signals induced 
by the phosphorylation (cf. Fig.5). Protein substrates, including the protein kinases situated 
thereon, will be toggled between active and inactive conformational states, depending upon 
their degree of phosphorylation  (Akamine, et al., 2005; Hunter, 1995).  
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Fig.5. Protein kinases and phosphatases. Protein kinases and phosphatases regulate biological signals by 
acting as enzymes that catalyze phosphorylation and dephosphorylation in biological organisms. Phosphorylation 
catalyzed by protein kinases retransmits incoming signals by activating the protein kinases’ substrates. Signal 
transmission will be terminated by dephosphorylation (inactivation) of their substrates, a reaction catalyzed by 
protein phosphatases. 
 
The 518 protein kinases known to be present in the human genome have been classified by 
comparing their sequences, which has allowed identifying protein-kinase families (Hanks, et 
al., 1988; Hanks and Hunter, 1995). Characterizations of human protein kinases have been 
designated “the human kinome” (Liu and Gray, 2006). A classification based on the amino-
acid sequence of the catalytic domain (or kinase domain) has segregated protein kinases into 
ten, distinct subgroups (Hanks and Hunter, 1995). The cAMP-dependent protein kinase 
(PKA) utilized in the studies reported in this dissertation belongs to the AGC-kinase family. 
 
Table 3. Classifications of protein kinases into subfamilies (Hanks and Hunter, 1995). 
 
o AGC-family (63 members) 
o CAMK-family (74 members) 
o CK1-family (12 members) 
o CMGC-family (61 members) 
o RGC-family (5 members) 
o STE-family (47 members) 
o TK-family (90 members) 
o TKL-family (43 members) 
o aPK (40 members) 
o Other protein kinases (83 members) 
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More than 400 human diseases have been directly or indirectly connected to protein kinases. It 
is also estimated that more than one-quarter of all pharmaceutical drug targets are protein 
kinases (Liu and Gray, 2006). Protein-kinase activity is controlled and regulated. However, 
perturbations of protein-kinase signaling by mutations and other genetic alterations can result 
in deregulation of kinase activity and the onset of tumorogenesis, which can cause malignant 
transformations (Pawson, 1994; Hunter, 2000; Reed, 1999). The design of small molecules in 
conjunction with cancer-drug discovery is aimed at inhibiting such tumorogenic activity. It is 
generally believed that targeting protein kinases in conjunction with drug discovery can retard 
tumor growth. Compounds are designed to inhibit those protein kinases that have been 
identified as therapeutic targets. (Blume-Jensen and Hunter, 2001; Katayama, et al., 2008; 
Hünenberger, et al, 1999; Melnikova and Golden, 2004). 
 
All protein kinases bind ATP and the ATP-pockets of the various protein kinases therefore 
contain many similar structures, which has raised concerns regarding whether protein kinases 
might be targeted using ATP-competitive inhibitors, without resulting in severe side effects. 
Nonspecific bonding by designed drug molecules to protein kinases other than those targeted 
could alter pathways of importance to normal cell signaling, and thus cause undesired side 
effects. As of the late 1980s, no protein-kinase inhibitors had entered human clinical trials. 
The matter of specificity, along with the relatively high ATP-concentrations (2 mM – 10 mM) 
present in cells raised questions regarding how competitive bonding to ATP-pockets should 
be addressed. A milestone in that process was the discovery of the rapamycin molecule. 
Rapamycin was initially found to have immunosuppressant properties due to its bonding to 
the cytosolic protein kinase, mTOR (or FKBP-12), and was approved for clinical use for 
preventing rejections following kidney transplantations in 1999. However, rapamycin was 
shown to inhibit tumor growth and approved for clinical use in the treatment of cancer 
(Davies, et al., 2000). A review of small-molecule inhibitors targeting protein kinase was 
published by Cherry and Williams (2004).  
1.3.1. PKA - the cAMP-dependent protein kinase 
The cAMP-dependent protein kinase (PKA) is one of the most commonly characterized of the 
protein kinases. PKA has served as a prototype for the extensive protein-kinase family 
(Taylor, et al., 2004). The catalytic subunit of PKA represents a prominent example of how a 
protein kinase both recognizes its substrates as well as inhibitors. It also shows how the 
enzyme moves through the stages of catalysis (Hünenberger, et al, 1999).  
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Early research revealed how the different zones and residues of PKA affect the kinetics and 
affinity of the phosphotransfer reaction occurring between protein kinase and its various 
substrates (Kemp, et al., 1977). Furthermore, PKA was the first protein kinase whose 
3-dimensional structure became known, a finding that has had an enormous impact on modern 
protein-kinase drug discovery (Cohen, 2002). PKA is unique among protein kinases due to the 
fact that the full-length, single-chain protein kinase is constitutively active in monomeric form 
and possesses only a single folding domain that consists of the core kinase catalytic domain 
and N-terminal and C-terminal extensions (Breitenlechner, et al., 2005). In its inactive state, 
PKA exists as a heterotetramer having two dimeric regulatory (R) subunits and two catalytic 
(C) subunits. Activation is achieved when cAMP bonds to those regulatory subunits (Choel, et 
al., 2006), which leads to the C-subunits being liberated from the R-subunits. After that, the 
C-subunits can bind ATP and interact with substrates. The catalytic subunit of PKA is 
potently inhibited (confined to the low-nM range) by a number of synthetic derivatives 
(Congreve, et al., 2005). In comparison, ATP forms bonds with an affinity (KD) falling within 
the 10-µM –20-µM range. Fig.6 presents an overview of the structure elements/segments 
involved and a description of the binding pocket of PKA’s catalytic subunit.  
 
The overall structure patterns occurring in PKA are similar to those of other protein kinases. 
Fig.6 is confined to depicting an overall description of protein kinase’s catalytic subunits, 
which are formed by two lobes designated the “small lobe” and the “large lobe.” A cleft, in 
which the ATP-nucleotide bonds, is formed between the two lobes. The two lobes are 
connected by a hinge segment that anchors and stabilizes the bonding of the nucleotide. 
Bonding of the nucleotide illustrates how several parts of the ATP binding cleft interacts with 
ATP-molecules. For example, a loop formed in PKA by residue 49-57 generates several 
phosphate interactions via its backbone. That loop has a structure, the glycine-rich loop, 
containing several glycine residues. An ion pair is formed between the nucleotide and the 
amine group on the catalytically important lysine residue in PKA, Lys-72, which is strongly 
preserved in protein kinases. The adenine ring of the nucleotide is situated deep within the 
pocket and forms two hydrogen bonds with the hinge segment. A further interaction with the 
residue Thr-183 present in PKA transpires. The magnesium ions are cofactors in kinase 
activity and bind via the aspartic acid present in DFG-motifs, Asp-184, the asparagine residue, 
Asn171, present in PKA’s catalytic loops, and the γ-phosphate, present in PKA’s 
ATP-molecules (Congreve, et al., 2005).  
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(A) 
 
Fig.6. The catalytic sub-unit of PKA. 
(A) An overview orientation image 
where the small lobe (blue) and the large 
lobe (red) are shown. The ATP binding 
cleft/pocket and the hinge zone are 
pointed out (orange). (B) A detailed 
image of the ATP binding mode in the 
catalytic subunit of PKA. Structure 
elements are marked and a selection of 
the interactions picked up by the ATP 
molecule is shown. The adenine moiety 
forms two hydrogen bonds with the 
hinge (orange) and interacts with the 
residue Thr-183 (purple). The phosphate 
groups interact with Lys-72 (blue) and 
the DFG-motif (purple). Both the 
glycine-rich loop (purple) and the PKI-
peptide (light-blue) cover the ATP-
pocket. 
(B) 
 
    
Another overview of the ATP binding pockets present in protein kinases has been published 
by Liao (2007) and defines several subpockets commonly addressed by small molecules 
binding to protein kinases (cf. Fig.7). ATP binding pockets on PKA are subdivided into 
various zones designated A, K, R, P, E0, E1, BP-I, and BP-II. 
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ATP-pocket zones defined by 
Liao 
A Adenosine binding site 
R Ribose binding site 
P Phosphate binding site 
K Catalytic lysine and DFG-motif 
E0 Pocket beneath the A/hinge zones 
E1 Hydrophilic, solvent-exposed pocket 
BP-1 Hydrophobic selectivity pocket 
BP-II Hydrophobic, back-cleft pocket 
Fig.7. The ATP binding pocket in cAMP-dependent protein-kinase A. An illustration of the zones defined by 
Liao for describing its ATP-pocket. Their designations are listed in the table at right. When ATP binds, the 
adenosine moiety is situated in the A-zone. The ribose is situated in the R-zone. Phosphate groups bind in the 
P-zone. BP-I- and BP-II-zones are situated above the A-zone in this view. The K-zone is situated between the 
A-, R-, BP-I-, and BP-II-zones. The E0- and E1-pockets are situated beneath the A- and R-zones, which are 
described as being hydrophilic, solvent-exposed zones. 
1.3.2. PROTEIN KINASES AND FBLD 
Extensive research has been devoted to the development of small-molecule drugs that target 
the ATP binding pocket in protein kinases. Fragment-based approaches have thus also been 
employed for detecting new chemical scaffolds in the protein-kinase drug-discovery field. The 
literature is replete with reports on fragment screenings targeting protein kinases that have led 
to development of potent inhibitors in conjunction with various projects (PKB: (Donald, et al., 
2007; Saxty, et al., 2007); p38 MAP: (Gill, et al., 2005); c-Src: (Taylor, et al., 2007); c-Met, 
aurora kinases: (Jhoti, et al., 2007); CK2, PDK1, and CHK1: (Hajduk and Greer, 2007); 
CDK2: (Congreve, et al., 2003); JNK3: (Fejzo, et al., 2003); and adenosine kinase (Hajduk, et 
al., 2000)).  
 
It has been pointed out that protein kinases contain the 21st-century’s most-interesting drug 
targets (Cohen, 2002). Programs aimed at finding new chemical scaffolds that interact with 
the ATP-pockets or other parts of proteins are thus of great interest, and FBLD offers one way 
of approaching that field of research (Lindsay, 2005). 
1.3. THE AIM OF THIS STUDY 
The pharmaceutical industry aims to increase the rate at which drug-discovery processes 
develop new, active, drug ingredient. Fragment-based lead discovery (FBLD) has been chosen 
as a tool for use in that effort and is emerging as an approach to small-molecule drug 
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discovery. Employment of FBLD has led to experimental techniques that allow characterizing 
interactions between low-molecular-weight fragments and disease target protein attracting 
greater interest on the part of those working in the drug-discovery field. Characterizations of 
the interactions between molecular fragments and target proteins can aid efforts to understand 
how results obtained from FBLD can aid the drug-discovery process. In the early days of such 
studies, the respective techniques involved were employed in investigations of various 
approaches to FBLD. However, no detailed characterizations of fragment-screening data 
obtained from combinations of them have been published to date. These studies therefore 
combined characterizations of the respective results obtained from surface-plasmon-resonance 
(SPR) analyses, high-compound-concentration biochemical assays (HCA), and protein 
crystallography. This study combines those techniques with the results of a second approach 
and discussions regarding how results extracted from available interaction data can make 
FBLD more useful in the development of new drugs. The outcomes, limits, and hit rates 
resulting from employment of those techniques in FBLD will also be discussed. 
 
The goals of this study were: 
• examining the characteristics, outcomes, and limits that result when SPR and HCA are 
employed as fragment-screening methods, 
• estimating screening hit rates that could be confirmed by protein-crystallography 
studies, 
• identifying fragment-like compounds that might serve as starting points for drug-
discovery programs, and 
• assessing how available assay data might be of use in efforts to create fragment-
protein complexes. 
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Chapter 2  
MATERIALS AND METHODS 
 
 
2.1. MATERIALS 
2.1.1. CHEMICALS 
All standard chemicals were either purchased from Calbiochem, Darmstadt, Germany, or 
requisitioned from in-house inventories maintained at Merck, Darmstadt, Germany, unless 
otherwise stated. 
2.1.2. INHIBITORS 
2.1.2. SMALL-MOLECULE INHIBITORS 
Solid-state H-89 (CAS 127243-85-0), packed in vials containing 1 mg per vial, was purchased 
from Calbiochem. All other inhibitors and compounds were requisitioned from MerckSer-
ono’s in-house inventories and either dissolved in “remp solution,” yielding 10-mM concen-
trations in 100 % DMSO, or employed in solid form in quantities of < 10 mg per compound. 
2.1.2.1. PEPTIDE INHIBITOR 
Solid-state PKI (Calbiochem), packed in vials containing 1 mg per vial. 
 
Sequence: Thr-Tyr-Ala-Asp-Phe-Ile-Ala-Ser-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile (6-22) 
http://www.merckbiosciences.co.uk/product/539684 
MWT: 1,868.1 Da 
CAS 121932-06-7 
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2.1.3. PROTEIN, HUMAN-PKA 
2.1.3.1. SEQUENCE 
MGNAAAAKKGSEQESVKEFLAKAKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFG
RVMLVKHKETGNHYAMKILDKQKVVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFKD
NSNLYMVMEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPE
NLLIDQQGYIQVTDFGFAKRVKGRTWTLCGTPEYLAPEIILSKGYNKAVDWWALGV
LIYEMAAGYPPFFADQPIQIYEKIVSGKVRFPSHFSSDLKDLLRNLLQVDLTKRFGNLK
NGVNDIKNHKWFATTDWIAIYQRKVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKC
GKEFSEF 
 
MWT: 40.56 kDa 
2.1.4. EXPERIMENTAL BUFFERS, SOLUTIONS, AND MATERIALS 
All buffers were prepared in the form of aqueous solutions. NaOH (2-M) and HCl (2-M) were 
employed for adjusting buffer pH. 
2.1.4.1. PROTEIN CRYSTALLOGRAPHY 
Protein-purification buffer 30.4 mg/ml PKA 
5 mM Mes 
5-mM bis-tris-propane/HCl 
75 mM LiCl 
0.1 mM EDTA 
1 mM DTT 
pH: 6.9 
Protein-crystallization buffer 5 mM MES 
5 mM bis-tris-propane 
75 mM LiCl 
1 mM DTT 
0.1 mM EDTA 
Protein-crystallization additives 1.4 mM MEGA-8 (Hampton Research, detergent screen I) 
1.5 mM PKI peptide inhibitor 
15 % – 25 % ethanol or methanol 
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Protein-crystallization and data- 
collection materials 
24-well VDX-plate, with sealant (Hampton Research) 
Siliconized-glass cover slides (Hampton Research) 
Seed-bead kit (Hampton Research) 
Vortexer (VWR International) 
Centrifuge (Eppendorf 5415) 
Seeding tool (Hampton Research) 
Cryoloop, installed (Hampton Research) 
Crystal cross-linking 100 % gluteraldehyde 
Protein crystallization buffer 
Microbridges (Hampton Research) 
Cryoloop, installed (Hampton Research) 
Crystal-stabilizing buffer/com-
pound-soaking buffer 
70 % protein-crystallization buffer 
30 % ethanol or methanol 
Cryoloop, installed (Hampton Research) 
Cryoprotectant conditioner 20 % L-(+)-2,3 butanediol (FLUKA #18967) 
20 % ethanol 
60 % protein-crystallization buffer 
Cryoloop, installed (Hampton Research) 
Data collection Cryoloop, installed (Hampton Research) 
Rigaku MicroMax microfocus X-ray generator (Rigaku 
Americas Corporation) 
R-axis IV++ detector (Rigaku Americas Cooperation) 
PX-I and PX-II sources (SLS) 
Pilatus detector (Brönnimann, et al., 2006) 
2.1.4.2. SURFACE-PLASMON-RESONANCE ANALYSES 
2.1.4.2.1. GENERAL MATERIALS 
BIACORE A-100 BIACORE 
Series-S CM5 sensor chip BIACORE 
BIAnormalizing solution BIACORE 
BIAmaintenance kit BIACORE 
HBS-N buffer BIACORE 
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Buffer stock solution 1 M HEPES 
1.5 M NaCl 
pH: 6.8 
PKA-protein, in buffer 30.5 mg/ml PKA 
5 mM Mes 
5 mM bis-tris-propane/HCl 
75 mM LiCl  
0.1 mM EDTA 
1 mM DTT  
pH: 6.9 
CA-protein, in buffer 30 µg/ml CA (BIACORE, S-51 training kit) 
Acetate buffer, pH: 5.5 (BIACORE) 
 
2.1.4.2.2. PROTEIN IMMOBILIZATION 
Normalizing solution BIACORE 
EDC BIACORE 
NHS BIACORE 
Ethanolamine BIACORE 
Running buffer used during protein 
immobilization 
100 mM HEPES (buffer “A”) 
150 mM NaCl (buffer “A”) 
0.005 % Tween 20 
2 mM MgCl2 
pH: 6.8 
Protein (PKA) immobilization buffer 10 mM bis-tris-propane 
200 µM ATP 
2 mM MgCl2 
Protein (CA) immobilization buffer Acetate buffer, pH: 5.5 (BIACORE) 
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2.1.4.2.3. COMPOUND SCREENING AND CHARACTERIZATION 
Running buffer 100 mM HEPES (buffer “A”) 
150 mM NaCl (buffer “A”) 
0.005 % Tween 20 
2-mM MgCl2 
pH: 6.8 
2 % DMSO 
Sample-preparation buffer 100 mM HEPES (buffer “A”) 
150 mM NaCl (buffer “A”) 
0.005 % Tween 20 
2 mM MgCl2 
pH: 6.8 
Positive-control sample (PKA) 1 mg H-89 dissolved in DMSO to yield a: 
1-mM solution in 100% DMSO (stock solu-
tion) 
Diluted in sample-preparation buffer: 
2 µM H-89 
2 % DMSO 
Positive-control sample (CA) 10 mM furosemide (BIACORE, S-51 train-
ing kit) 
100 % DMSO 
Diluted in sample-preparation buffer: 
20 µM furosemide (BIACORE) 
2 % DMSO (Merck) 
Negative-control sample Running buffer 
Solvent-correction setup Sample preparation buffer containing 
1.2 % DMSO 
1.4 % DMSO 
1.6 % DMSO 
1.8 % DMSO 
2.0 % DMSO 
2.2 % DMSO 
2.4 % DMSO 
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2.6 % DMSO 
2.8 % DMSO 
Compound-screening preparation 10 mM compound in “remp-tube” 
100 % DMSO 
Diluted in sample preparation buffer: 
200 µM compound 
2 % DMSO 
Compound-characterization preparation Solid-state compound dissolved in stock 
solutions 
100 mM compound in 
100 % DMSO 
Diluted in sample preparation buffer: 
1 mM compound 
2 % DMSO 
1:1-dilution in sample preparation buffer in 
ten increments: 
1.0 mM compound, 2 % DMSO 
500 µM compound, 2 % DMSO 
250 µM compound, 2 % DMSO 
125 µM compound, 2 % DMSO 
62.5 µM compound, 2 % DMSO 
37.25 µM compound, 2 % DMSO 
15.63 µM compound, 2 % DMSO 
3.91 µM compound, 2 % DMSO 
1.95 µM compound, 2 % DMSO 
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2.1.5. COMPUTER SOFTWARE 
Library-generation and virtual-
screening software 
ZINC (UCSF, http://zinc.docking.org/) (Irwin and 
Shoichet, 2005) 
ISIS Base (MDL Information Systems, Inc.) 
ISIS Draw (MDL Information Systems, Inc.) 
Accord for Excel (Accelrys, Inc.) 
MOE (Chemical Computing Group, Inc.) 
SpotFire (Tibco Software, Inc.) 
SPR-software BIACORE A-100 Control 
BIACORE A-100 Evaluation 
BIACORE T-100 Control 
BIACORE T-100 Evaluation 
BIACORE S-51 Control 
BIACORE S-51 Evaluation 
BIACORE 3000 Control 
BIACORE 3000 Evaluation 
Accord for Excel 
ISIS Base (MDL Information Systems, Inc.) 
ISIS Draw (MDL Information Systems, Inc.) 
Protein-crystallography software ADXV (The Scripps Research Institute) 
XDS (Kabsch, 1993) 
Mosflm, Version 7.0.4 (Leslie, 1992) 
HKL2000, Version 0.97.647 (Otwinowski, et al., 1997) 
d*Trek, Version 9.9.2L (Pflugrath, 1999) 
CNS/CNX (Brunger, et al., 1998) 
Molrep (Vagin, 1997) 
CCP4 Suite (STFC Daresbury Laboratory) 
WhatIF (Vriend, 1990) 
COOT (Emsley and Cowtan, 2004) 
PyMol (DeLano, 2002) 
 
General software Microsoft Office (Microsoft Corporation) 
Adobe Acrobat 8.0 (Adobe Systems, Inc.) 
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2.2. METHODS 
Every molecular-biology protocol employed during cloning and purification has been 
described in detail by Yonemoto and by Engh (Yonemoto, 1997; Engh, 1996). MerckSerono’s 
in-house Protein-Expression Department and Purification Department were commissioned to 
perform that work. In brief, the catalytic subunit of human PKA was expressed in cytosolic 
expressions in E-coli BL21 (DE3) cells. Expressed biomass was purified by affinity 
chromatography and ion-exchange chromatography. Protein purification yielded 
approximately 20 mg of protein per 200 g of biomass. The purified protein was divided into 
two batches and concentrated to 20.5 mg/ml and 30.4 mg/ml, respectively, and stored in the 
protein-purification buffer following plunge-freezing in liquid nitrogen at – 80°C. 
2.2.1. PROTEIN CRYSTALLOGRAPHY  
Crystals and Symmetry 
In FBLD, protein crystallography is utilized for describing fragments’ three-dimensional 
binding modes in proteins. Protein crystals are formed when protein molecules precipitate out 
of solutions in the form of well-ordered solids. The orderings involved are three-dimensional 
arrays of atoms and molecules forming infinitely repeatable building blocks (asymmetric 
units) arranged in accordance with well-defined symmetries (65 distinct space groups in the 
case of proteins, 230 such altogether). A single asymmetric unit contains all of the 
information available on the crystal, where one or more protein molecules will be packed into 
each cell, depending upon the particular packing symmetry involved. 
 
Protein crystallography is reliant upon the availability of protein crystals that may be analyzed 
by means of X-ray diffraction. Experiments are necessary in order to determine suitable 
conditions for the formation of well-ordered protein crystals. Solutions of proteins are brought 
to the saturation point in order to cause nucleation and arrive at well-regulated crystal growth 
(McPherson, et al., 1995). The experimental parameters involved, such as solution pH, 
temperature, and ionic strength, are then optimized. Choices of protein buffer solutions, 
precipitate reagents, salts, and detergents also affect crystal growth (McPherson, 1982). 
Protein purities and concentrations also play important roles in efforts to obtain high-quality 
protein crystals. Fig.8 presents a solubility plot illustrating the protein-crystallization process. 
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Fig.8. Solubility plot for proteins. A plot of dissolved-protein concentration, Cprotein, against salt concentration 
or other parameter. Protein crystals begin to form at supersaturation levels below those at which nucleation 
occurs. Once nucleation occurs, dissolved-protein concentration declines. The solution then enters the metastable 
zone and stable protein-crystal growth sets in. The protein that subsequently precipitates out attaches itself to the 
surfaces of nuclei, allowing larger crystals to form. 
 
Automating crystallization experiments has become a common approach to determining 
suitable crystallization conditions. Robots capable of servicing several hundred to more than 
one-hundred thousand experimental setups daily have made large-scale, automated, 
crystallization experiments possible (Kuhn, et al., 2002). Techniques for automating the 
design of the chemical structures of proteins that will be soluble up to high concentrations and 
suitable for use in crystallization experiments are also available (Gilbert and Albala, 2002; 
Lesley, 2002). Investigations involving large numbers of experimental setups may also be 
conducted in more highly automated manners by taking advantage of advances in the areas of 
crystal storage and automated monitoring of experimental runs. A comprehensive review of 
crystallization techniques appears in the volume edited by Bergfors (Bergfors, 1999). 
 
PKA-crystallization 
cAMP-dependent protein kinase (PKA) must be regarded as one of the most-accurately 
characterized protein kinases, in view of the large number of published studies regarding it. 
The structure conformations, protein expressions, purification stages, and crystallization 
conditions have all been optimized for numerous, distinct sets of assay parameters. 
Employment of the resultant experimental conditions and PKA as target in order to 
characterize fragment-protein interactions were regarded as the best choice for the work 
undertaken in conjunction with the present dissertation. 
 
37 
  
PKA-crystallization protocols have been described by Bonn, et al. (2006), where purified 
protein at a concentration of 30.4 mg/ml was thawed following storage at – 80°C. The protein 
vials employed contained 25 µl protein per vial. MEGA-8 and PKI peptide inhibitor were 
added to the protein and the mixture diluted in protein-crystallization buffer to a theoretical 
protein concentration of 17 mg/ml. The solution was then centrifuged at 20°C and 6,000 g for 
1 minute in an Eppendorf 5415D centrifuge. Adhering droplets were set to have volumes of 
1 µl. They therefore contained 17 mg/ml PKA, 5 mM MES, 5 mM bis-tris-propane (pH: 6.5), 
75 mM LiCl, 0.1 mM EDTA, 1 mM DTT, and 1.5 mM PKI (5-24) peptide. The adhering 
droplets were then equilibrated at 4°C over a grid consisting of 15 % – 25 % (v/v) methanol 
and ethanol. Streak-seeding was conducted approximately 1 hour after commencement of the 
experiment using crystals that had been grown a few days earlier on a setup employing the 
same conditions, but without employment of streak-seeding. Seed crystals were collected by 
mixing adhering droplets containing crystals in a 1:1-ratio with crystal-stabilizing solution. 
The adhering droplets involved, which had volumes of approximately 2 µl, were then 
transferred to an Eppendorf seed-bead kit (Hampton Research) and vortexed for two minutes 
on a VWR International vortexer. Dipping a seeding tool into the Eppendorf seed-bead kit and 
streak-seeding droplets adhering to the crystallization plate resulted in overnight growth of 
PKA-crystals. 
2.2.1.1. FRAGMENT SOAKING AND COCRYSTALLIZATION 
Various methods may be employed for forming fragment-protein complexes. The protein may 
be co-expressed with the ligand, the ligand may be added at the protein-purification stage, 
cocrystallization may be utilized, or protein crystals may be soaked in a solution of the ligand 
(Hassel, et al. 2007). In the case of the type of setup involved here, both soaking and 
cocrystallization methods have been employed, but the soaking method has been that most 
extensively employed. Under the soaking method, protein crystals are soaked in a solution 
containing ligand molecules. Ligand molecules then diffuse into protein-binding sites, where 
they bind protein molecules to the latter, due to a particular mode of interaction. One of the 
major aspects to be considered when working with fragments is the need for obtaining 
sufficiently high occupancies of protein-binding sites. Protein crystallography involves 
coherently accumulating diffraction signals from the protein molecules present in crystals. 
Fragment molecules present in protein-binding pockets should therefore contribute to 
coherently accumulated diffraction signals. If the occupancies of protein-binding pockets are 
too low, fragment electron densities will not be observed. A rule-of thumb in protein 
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crystallography is employing fragment concentrations that are at least five times those needed 
for affinity. However, it has been found that when protein crystallography is utilized in 
FBLD, the solubilities of the fragments involved frequently limits the fragment concentrations 
that may be employed.  
 
The soaking procedures employed 
Fragment concentrations in the 100-mM, 100 % DMSO, stock solutions were diluted to the 
soaking concentrations in crystal-stabilizing buffers. Soaking investigations were conducted 
on an adhering-droplet setup, where 2-µl droplets containing the compound-soaking solution 
and 300 µl – 500 µl crystal-stabilizing buffer were inserted into the well in order to preclude 
the adhering droplets drying out. The fragment concentration in the soaking solution was 5 
mM in 5 % DMSO. Soaking was conducted for approximately 24 h at 4°C. Crystals were 
initially transferred from crystallizing droplets to the soaking solution. Those transferrals were 
cautiously conducted in order to avoid damaging the crystals. Soaked crystals were briefly 
immersed in the cryoprotectant solution (20 % ethanol, 20 % L-(+)-2,3-butanediol, and 60 % 
well solution taken from the wells where crystals had grown) prior to plunge-freezing them in 
liquid nitrogen at – 80°C. All transferrals of the crystals were conducted via the Hampton 
Research cryoloop that had been installed on the setup. 
  
Soaking conditions were individually optimized for each fragment, where a second or third 
round of soaking proved necessary. An initial stage involved a switch to employing higher 
compound/DMSO-concentrations (20 mM compound in 20 % DMSO). In addition, soaking 
periods were extended to as long as four days, depending on crystal stabilities in the 
compound-soaking solution. Crystal stability was manually checked under a microscope at 
intervals of approximately 24 h, 48 h, and 72 h. 
 
Crosslinking PKA-crystals 
The protein crystals obtained were not always stable under the soaking conditions employed. 
Many of them either broke or failed to yield diffraction patterns during soaking investigations. 
One way to eliminate such crystal instability is cross-linking the protein crystals (Lusty, 1999; 
Cohen-Hadar, et al., 2006; Roy and Abraham 2003), which stabilizes them and allows making 
more changes in protein structures without destroying the crystals involved, which, in turn, 
can increase success rates in efforts aimed at obtaining the structures of complexes.  
 
39 
  
The cross-linking conducted utilized gluteraldehyde and was applied to those cases where 
initial soakings had led to PKA-crystals losing their diffraction patterns. The PKA-crystals 
involved were emplaced in droplets adhering to cover slides containing 2 µl crystal-stabilizing 
solution suspended above a Hampton Research microbridge. 300 µl – 400 µl crystal-stabiliz-
ing solution was transferred to the well in order to prevent droplets from drying out. 8 µl 
gluteraldehyde was transferred to the microbridge and the PKA-crystals were immersed in 
evaporating gluteraldehyde for 2 h at 4°C. The PKA-crystals involved were then transferred to 
the compound-soaking solution. Investigations of the diffraction patterns of each such 
PKA-crystal following soaking revealed that the various soakings employed had damaged 
them. 
2.2.1.2. X-RAY DATA COLLECTION AND STRUCTURE DETERMINATION 
In 1896, Röntgen published a paper reporting the properties of X-rays, including their failure 
to demonstrate interference, reflection, or refraction effects on ordinary optical apparatus. In 
1912, von Laue was able to show that X-rays yielded diffraction patterns due to interferences 
with the lattice spacings of a CuSO4·5H2O-crystal. In that same year, Bragg was able to 
provide a valid explanation for the incidence of spots on X-ray-diffraction patterns and the 
new science of X-ray crystallography was born. Röntgen’s observations also led to him 
concluding that no substance can be utilized for focusing X-rays. However, diffracted X-rays 
may be combined analytically with the aid of computers, provided that X-ray-diffraction 
patterns are measurable. X-ray-diffraction experiments allow measuring the intensities of 
diffracted X-rays. However, recording diffraction patterns destroys all information on the 
relative phases of the diffracted X-rays that produced them. Since knowledge of both the 
phases and intensities of the diffracted X-rays is essential to reconstructing the images of 
diffracting objects, determining their phases represents the fundamental problem in all 
crystallographic analyses.  
 
Bragg’s law describes X-ray scattering by crystals in terms of reflections from crystal planes. 
Crystal planes illuminated at a grazing angle of incidence, θ, scatter X-rays at an angle of 
reflection that is also equal to θ. The incident and diffracted rays and the normals to the 
diffracting planes all lie in the same plane. Constructive interference between rays scattered 
from adjacent crystal planes will only occur if the path difference between the rays equals an 
integral number of wavelengths. If the spacing of adjacent crystal planes is d, the path differ-
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ence between two rays, ray 1 and ray 2, will be AB + BC = 2d sin θ = nλ. For constructive 
interference, we then have that 
 
2d sin θ = nλ,        (Eq. 2) 
 
where λ is the X-ray wavelength and n is an integer.  
 
Since the interaction between X-rays and matter is weak, interactions between single mole-
cules and X-rays are unobservable. Molecules must therefore be crystallized, i.e., arranged in 
regular arrays, which will cause the scattering from any, given molecule to be reinforced by 
that from of all other molecules. The diffraction patterns of molecular crystals may be referred 
to as their “molecular transforms,” i.e., the Fourier transforms of the molecules contained in 
the crystals. The three-dimensional lattices of molecules in crystals give rise to diffraction 
patterns, where the location of each spot thereon is governed by the underlying molecular 
transform at that location. In general, every part of molecules contributes to every part of 
diffraction patterns. Conversely, in order to reconstruct molecules’ structures from their 
diffraction patterns, it will be necessary to measure the intensity of every spot on their 
diffraction patterns. When an X-ray beam interacts with matter, scattering occurs from two 
types of processes, coherent scattering and incoherent scattering. The electromagnetic field of 
the incident X-ray beam forces the electrons in the matter involved into oscillations at the 
same frequency as that of the incident beam. All rays scattered by a given electron will thus 
have the same phase relative to the incident beam, and the resultant scattering will be 
coherent. The intensity of the scattered beam is inversely proportional to the mass of the 
scattering entity. The fact that the proton mass is approximately 2,000 times the electron mass 
thus explains why only the electrons in crystals contribute to coherent scattering. In X-ray 
crystallography, the incoherent scattering is much weaker than the correlated, coherent scat-
tering and is thus usually ignored. 
 
The total intensity scattered by a crystal is the sum of the intensities of all rays scattered by all 
unit cells involved. The von Laue equations are mathematical relations that describe that 
summation in three-dimensional space. Knowledge of proteins’ diffraction patterns and 
applications of Fourier transforms will allow computing their crystalline structures. However, 
the phase problem remains to be solved. In order to compute their electron densities, the 
phases of all diffracted waves will be needed. The phase problem may be solved by different 
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methods, Patterson summation, direct methods, heavy-atom isomorphous replacement, or by 
analyzing anomalous scattering patterns. Molecular replacement can employ homologue 
crystalline structures in order to obtain phases via Patterson summation. The phases obtained 
for the homologue structure are utilized as initial estimates of phases for the unknown 
structure. That model is termed the “phasing model” and is mapped onto the unit cell of the 
unknown structure. Computing the Patterson functions for a random cell and superimposing 
them allows determining the orientations of the two models. Once a set of initial phases has 
been obtained, a trial structure may be configured and improvements and thermal parameters 
that will bring it into the closest-possible conformity with reality sought. “Reality,” as used 
here, means the set of observable amplitudes/intensities contained in the X-ray diffraction 
pattern in question. Observed and computed structure factors should agree, to within the 
tightest tolerances possible. The progress of refinements at each stage is usually assessed in 
terms of a reliability index, R, or R-factor, which is given by  
 
 
 ,   (Eq. 3)
 
 
where Fobs are the observed structure factors and Fcalc are those obtained from the 
computational model. A cross-validation scheme based on the so-called R-free factor 
(Brünger, 1992) employs a test-data set that is ignored under the refinements, but for which an 
R-factor is computed, provides indications regarding how well the model predicts empirical 
observations that were not used in fitting the model to the empirical data. Since the 
differences between the conventional R-factor and the R-free factor, R-free – R, are partly a 
measure of the extent to which the model overfits the empirical data, they should be small. 
 
There are several means for refining the protein structure model. The phases involved may be 
refined, they may be extended to higher resolutions, and the fit of the model to computed 
electron densities may be improved. Knowledge of protein chemistry is required there, and the 
improvements obtained will depend upon the correctness of the interpretations of electron-
density data. Such incremental refinements are typically pursued with the aid of computer 
programs that have been specially developed for use in protein crystallography. 
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PKA-data collection and structure refinements 
X-ray diffraction data was collected following transferrals of PKA-crystals to the cryoprotec-
tant solution and plunge-freezing in liquid nitrogen. The PKA-crystals were cooled by a 
100-K stream of liquid nitrogen while X-ray-diffraction data was being collected. The Swiss 
Light Source (SLS) PXI and PXII beamlines and in-house MerckSerono rotating-anode 
source were employed as X-ray sources. The in-house source employs graphite, 
monochromatized CuKa radiation from an RU 200 rotating-anode generator (Rigaku, Tokyo, 
Japan). The in-house detector is a Rigaku R-AXIS IV X-ray detector, and, at SLS, the Pilatus 
detector at PXI was employed in collecting diffraction data. Data reduction was conducted 
using XDS, HKL2000 (Otwinowski, et al., 1997), or d*Trek. Data were integrated and scaled 
using HKL2000, XDS, d*Trek, SCALA, and MOSFLM. All structures were derived from 
molecular replacements employing Molrep. The initial molecular-replacement model 
employed was the PKA-structure 1ATP (Zheng, et al., 1993), downloaded from PDB 
(Bernstein, et al., 1997), with ligand and water molecules removed. Structure-model 
refinement and ligand fitting employed CNX (Brunger, et al., 1998) and COOT (Emsley and 
Cowtan, 2004). Following ligand fitting, subsequent cycles of model adjustment and 
refinement were carried out using COOT and CNX. Refined protein structures where checked 
and validated using WhatIF (Vriend, 1990). 
2.2.2. SURFACE-PLASMON-RESONANCE ANALYSES  
Surface-plasmon-resonance (SPR) analysis is an optical technique that measures changes in 
refractive index close to a sensor’s surface employing the evanescent-wave phenomenon. In 
the case of the setup employed for this dissertation, the target protein (PKA) is immobilized 
on the sensor’s surface and molecules (fragments) are injected into a stream flowing over the 
sensor’s surface. The fragments thus interact with the target protein and generate a response 
that was recorded in real time. Fig. 9 schematically depicts the basic interactions involved.  
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Fig. 9. Schematic of the SPR technique. Protein molecules (B) are attached to the dextrane matrix on the 
sensor’s surface. Fragment molecules (A) are injected into a stream passing over the sensor’s surface. ka and kd 
are intrinsic rate constants that describe the formation of complexes involving the fragments (A) and the protein 
(B). (adapted from a figure appearing in Myszka, (1997)) 
 
Detection relies upon surface plasmon resonance (SPR), an electron-charge-density wave 
phenomenon that arises at the surface of a metallic film when light is reflected at the film 
under conditions of total internal reflection (TIR). The resonance is due to transformations of 
the energies and momentum of incident photons into surface plasmons, which depends upon 
the refractive index of the medium on that side of the film opposite that from which the 
incident light is reflected. SPR monitors interactions between the protein and the fragments by 
measuring the changes in solute concentration occurring at the latter surface due the 
interactions taking place between the protein and fragments. The result is a change in the 
surface-plasmon-resonance signal, expressed in response units (RU) (cf. Fig.10).  
 
 
Fig.10. SPR-detection. Interactions between fragments injected into the flow channel and proteins attached to 
the sensor’s surface cause a change in the refractive index of the underlying material, close to its upper surface, 
which alters the angle of incidence (SPR-angle) required for generating SPR. The SPR-angle is monitored in the 
form of a resonance signal, expressed in RU, by tracking changes (from I to II) in the angle of reflection.  
 
SPR-sensorgrams 
A plot of resonance units versus time is termed a “sensorgram” (GE Healthcare, Application 
Note 83). A sample sensorgram is shown in Fig.11, which schematically depicts the various 
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phases of SPR-analyses. In the case of the investigations reported here, the stream of buffer 
solution is brought into contact with the surfaces of immobilized proteins prior to fragment 
injection, yielding a response baseline. Fragments are then injected into the stream (the associ-
ation phase) and binding of fragments entrained in the stream to the protein causes a rise in 
response (binding response, expressed in RU). Once fragments have been injected into the 
stream, the flow rate is readjusted only in order to contain the flow of buffer solution. Halting 
the injection of fragments triggers the dissociation phase. As fragments and the protein dis-
sociate and fragments are swept off the latter’s surface, signal amplitude will decline to the 
baseline level. 
 
 
 
Fig.11. A sample SPR-sensorgram. Sensorgrams plot binding response, expressed in RU, versus time and 
therefore provide real-time data on overall fragment-protein interactions. The plot shown above is typical of 
fragments exhibiting transient binding responses. When injection starts, a signal indicating that fragment 
binding is occurring will be observed. When injection stops, fragment dissociation from the protein’s surface 
will commence and signal amplitude will abruptly drop to the baseline level.  
 
Fragments have low molecular weights and frequently have binding constants falling in the 
µM to mM range. Binding of a fragment to a surface thus results in relatively small mass 
increases close to the binding surface and low-level SPR-responses. The resultant low 
signal/noise ratios thus impose limitations when working with fragments. SPR fragment 
assays employ high protein and fragment concentrations in order to boost signal amplitudes to 
levels well above noise levels.  
The fragments involved are dissolved in an organic solvent in order to ensure that they will 
continue to be soluble at high concentrations. A commonly used solvent for small molecules 
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is DMSO, which has a high refractive index. A slight mismatch in DMSO concentration 
between the running buffer and sample buffer can thus cause large signal mismatches that can 
greatly exceed responses generated by fragment-protein interactions. A 0.1 % difference in 
DMSO concentration corresponds to a response shift of approximately 200 RU. Corrections 
for response shifts due to changes in the DMSO’s refractive index should thus be determined 
by measuring the signals transmitted on the protein-free reference channel (Cannon, et al., 
2004; Huber, 2005). Solvent-correction runs employing buffer injections involving controlled 
DMSO concentrations will allow correcting for such signal variations. 
SPR-signals are sensitive to even the slightest variations in solution refractive index. A 
reference-spot check may be run in order to determine whether responses are partially 
attributable to interactions other than fragment-protein interactions. Reference-spot binding 
responses are then subtracted from protein-spot binding responses in order to obtain just those 
responses originating from fragment-protein interactions. 
Under the experimental procedures employed in the work reported in this dissertation, 
proteins are immobilized on the sensor’s surface prior to fragment injection. Immobilization 
of proteins on the sensor chip’s surface set the protein quantity, or concentration, that should 
be used in fragment assays. Immobilization of proteins should also ensure that they will be 
maintained states that will allow them to bind fragments (Huber, 2005). Protein activity levels 
may be computed by employing a control compound having a known binding stoichiometry, 
where N represents the total number of bound compound molecules per immobilized protein 
molecule, i.e., the protein activity level, and is given by 
  
(Eq. 4)
 
 
 The protein-binding levels, Rprotein, the saturation response, Rmax, of the positive control 
compound, Rreference, protein molecular weight, MWTprotein, and the molecular weight of the 
positive control compound, MWTreference, all represent parameters that can be measured. The 
ratios (δn/δC)reference and (δn/δC)protein, represent the change in refractive index caused by 
variations in the concentrations of bound protein or bound compound, and are constants for 
given molecules and usually unknown. They are therefore neglected in most SPR-applications 
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(Huber and Mueller, 2006). Measuring protein activity levels following immobilization is 
recommended. Experience has shown that large variations in protein activity levels between 
differing protein surfaces can occur (Huber and Mueller, 2006). Protein activity levels are 
routinely checked several times during fragment-screening campaigns. Control compounds 
yield the activity levels of individual immobilized surfaces and also provide some degree of 
control over the stabilities of protein surfaces, since they are employed during several cycles 
interposed between fragment injections during screening. The variations in activity levels and 
expected fragment-binding signals occurring throughout screening may then be computed. 
Unexpected reductions in activity levels can lead to erroneous estimates of the numbers of 
bound fragment molecules.  
2.2.2.1. PKA ASSAY PREPARATION 
Sensor-chip quality checks 
All SPR-investigation were carried out at 25°C using a BIACORE A-100 instrument (GE 
Healthcare, Uppsala, Sweden). A fresh CM5 sensor chip was employed on each new experi-
mental setup. The immobilization program employed was that provided by the BIACORE A-
100 control software. BIAnormalize solution (BIACORE) and HBS-N buffer (BIACORE) 
were employed in accordance with the instructions displayed by the software. The control-
software settings employed were precisely those specified by the instrument’s manufacturer. 
BIACORE A-100 BIACORE 
Series S sensor chip CM5 BIACORE 
BIAnormalize solution BIACORE 
BIAmaintenance kit BIACORE 
HBS-N Buffer BIACORE 
 
Immobilization 
PKA was coupled to the CM5 sensor chip’s surface via amine-coupling chemistry. Free 
carboxylic-acid groups in the dextrane matrix were transformed into N-hydroxysuccinimide 
esters, which was achieved by injecting carbodiimide (EDC) and N-hydroxysuccinimide 
(NHS), which reacts with the free carboxylic-acid groups. Coupling occurs largely with the 
free amino groups of lysine residues. Following immobilization of the protein, ethanolamine 
was applied to the sensor’s surface in order to deactivate any active groups remaining on its 
surface. The amine coupling reagents EDC, NHS, and ethanolamine (BIACORE), which were 
kept in storage at – 20°C, were withdrawn from storage and thawed. Prior to application, it 
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was verified that the immobilization reagent to be employed contained no air bubbles. The 
following protocols list the settings employed in immobilizing PKA on the sensor chip’s 
surface. Fig.12 presents an overview of the instrumental layout for this particular setup of the 
BIACORE A-100. 
 
 
Fig.12. The five detection areas employed in immobilizing protein on the sensor chip. PKA was immobi-
lized on three spots at three, differing, protein-density levels. The immobilized protein levels involved corres-
ponded to response levels of 10 k, 6 k, and 3 k. CA was immobilized on a single spot employed as a reference 
spot in order to allow investigating nonspecific protein interactions. One spot was employed as a vacant surface 
and revealed that interactions with the sensor chip’s surface were occurring. 
 
BIACORE A-100 control software was employed, where the settings for the immobilizations 
involved were as follows: 
Immobilization conditions 
Sensor chip CM5 
Channels/spots Fc1, Fc2, Fc3, and Fc4; spots 1 – 5 
Flow rate 10 µl/min 
Temperature 25°C 
Channel 1/2/3/4 
Spot(s) 1, 2, and 4 
Immobilization mode Amine coupling 
Ligand/protein Human PKA(10 – 350)  
Protein concentration 20 µg/ml (spots 1 and 2) and 10 µg/ml (spot 4) 
Sample buffer 10 mM bis-tris-propane, pH: 6.5 
Sample preparation 1:200 dilution of the ligand in Milli-Q-H2O 
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Injection time 240 s + 240 s (spot 1) 
240 s (spot 2) 
120 sec (spot 4) 
Running buffer Immobilization running buffer 
BIACORE A-100 BIACORE 
Series-S CM5 sensor chip BIACORE 
Normalizing solution BIACORE 
HBS-N buffer BIACORE 
Normalization 1 BIACORE 
Normalization 2 BIACORE 
EDC BIACORE 
NHS BIACORE 
Ethanolamine BIACORE 
Human PKA protein/protein-
immobilization buffer 
20.5 mg/ml PKA 
5 mM Mes 
5 mM bis-tris-propane/HCl 
75 mM LiCl  
0.1 mM EDTA  
1 mM DTT  
pH: 6.9 
CA-protein/protein-immobiliza-
tion buffer 
30 µg/ml CA (BIACORE, S-51 training kit) 
Acetate buffer, pH: 5.5 (BIACORE) 
Protein immobilization running 
buffer 
100 mM HEPES 
150 mM NaCl 
0.005 % Tween 20 
2 mM MgCl2 
pH: 6.8 
PKA-protein immobilization 
buffer 
10 mM bis-tris-propane 
200 µM ATP 
2 mM MgCl2 
CA-protein immobilization 
buffer 
Acetate buffer, pH: 5.5 (BIACORE) 
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2.2.2.2. FRAGMENT SCREENING 
Fragment screening involves injecting fragments into a stream of solution at a single 
concentration in order to determine whether they interact with the protein immobilized on the 
sensor’s surface. The resulting sensorgrams are then analyzed in order to pick out the hits. 
An expected maximum response due to fragments binding at equilibrium may be computed 
for each fragment molecule. During fragment screenings, such computations are utilized for 
identifying those fragments that interacted with the protein on a 1:1-basis at the molecular 
level. The theoretical maximum binding responses for such 1:1-interactions, Rmax, may be 
computed from the molecular weights of the fragment and protein involved, the quantity of 
protein immobilized on the sensor chip’s surface, and the immobilized protein’s activity level, 
employing the following relation: 
 
(Eq. 5) 
Upon binding, chemical scaffolds can cause the occurrence of unexpected refractive-index 
increments (RII) on the sensor chip’s surface (Davis and Wilson, 2000), which can result in 
the binding responses obtained differing from those expected in the case of certain affinities 
and molecular weights. Employing an upper cutoff level of 2Rmax as a criterion in hit-
classification surveys is therefore recommended in order to preclude inclusion of fragments 
whose refractive-index increments are due to their molecular properties. 
Signal/noise ratios determine the lowest cutoff levels for which fragment binding responses 
may be regarded as reliable and both represent the minimum response levels that will be 
reliably detected and define those fragments that will be counted as hits at the fragment 
concentration employed in screening. Assignments of lower cutoff levels are based on the 
average responses received from negative controls, plus three standard deviations.  
Responses that occur upon fragment binding will be observed in the form of signal transients 
exhibiting very short rise and fall times (cf. Fig.11). The rates at which steady-state binding, 
i.e., binding equilibrium, is reached equal the product of the association constant, kon or ka, 
and the free-fragment concentration. Under such circumstances, transient binding behavior is 
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to be expected in the case of virtually all fragments. In this study, such sensorgrams were 
therefore classified as typical transient-binding sensorgrams. 
 
A compound concentration of 200 µM was employed in fragment screenings. Fragments were 
flowed onto sensor surfaces bearing immobilized PKA. The fragments involved were 
prepared by MerckSerono’s in-house Compound-Storage Department. The stock solutions 
employed contained 10-mM fragment concentrations in 100 % DMSO. Those stock solutions 
were diluted in Eppendorf tubes to sample-preparation-buffer levels in a single operation. The 
Eppendorf tubes containing the diluted compound solutions were then vortexed for 5 seconds 
in a VWR International vortexer. Compound solutions were subsequently transferred from the 
Eppendorf tubes to a BIACORE 386 well plate, which was subsequently sealed using 
BIACORE sealing film pending usage. Running buffer, sample-preparation buffer, solvent 
(DMSO) corrections, positive and negative control samples, fragment samples, and surface-
regeneration conditioner were all prepared in accordance with the following table: 
 
Running buffer 100 mM HEPES 
150 mM NaCl 
0.005 % Tween 20 
2 mM MgCl2 
pH: 6.8 
2 % DMSO 
Sample-preparation buffer 100 mM HEPES 
150 mM NaCl 
0.005 % Tween 20 
2 mM MgCl2 
pH: 6.8 
PKA positive-control sample 1 mg H-89 dissolved in DMSO to yield: 
1 mM 100 % DMSO (stock solution) 
Diluted in sample-preparation buffer: 
2 µM H-89 
2 % DMSO 
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CA positive-control sample 10 mM furosemide (BIACORE, S-51 train-
ing kit) 
100 % DMSO 
Diluted in sample preparation buffer: 
20 µM furosemide (BIACORE) 
2 % DMSO (Merck) 
Negative-control sample Running buffer 
Solvent-correction setup Sample-preparation buffer containing 
1.2 % DMSO 
1.4 % DMSO 
1.6 % DMSO 
1.8 % DMSO 
2.0 % DMSO 
2.2 % DMSO 
2.4 % DMSO 
2.6 % DMSO 
2.8 % DMSO 
Screening compounds 10 mM compound in “remp tubes” 
100 % DMSO 
Diluted in sample preparation buffer: 
200 µM compound 
2 % DMSO 
Characterization compounds 100 mM compound in stock solutions 
100 % DMSO 
Diluted in sample preparation buffer: 
1 mM compound 
2 % DMSO 
1:1-dilution in sample-preparation buffer in 
ten increments: 
1.0 mM compound, 2 % DMSO 
500 µM compound, 2 % DMSO 
250 µM compound, 2 % DMSO 
125 µM compound, 2 % DMSO 
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62.5 µM compound, 2 % DMSO 
37.25 µM compound, 2 % DMSO 
15.63 µM compound, 2 % DMSO 
3.91 µM compound, 2 % DMSO 
1.95 µM compound, 2 % DMSO 
 
The BIACORE A-100 control software was configured with the following experimental 
settings: 
 
Chip conditioning  
Solution, flow cell 1 Running buffer A 
Solution, flow cell 2 Running buffer A 
Solution, flow cell 3 Running buffer A 
Solution, flow cell 4 Running buffer A 
Contact period, cycles 1 – 5 180 s 
Total no. of cycles 5 
Extra wash, flow cell 1 50 % DMSO 
Extra wash, flow cell 2 50 % DMSO 
Extra wash, flow cell 3 50 % DMSO 
Extra wash, flow cell 4 50 % DMSO 
Stabilization period prior to injection N/A 
Stabilization period following injection 180 s 
Flow rate 30 µl/min 
Samples  
Sample buffer, flow cell 1 Sample in running buffer  
Sample buffer, flow cell 2 Sample in running buffer 
Sample buffer, flow cell 3 Sample in running buffer 
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Sample buffer, flow cell 4 Sample in running buffer 
Running buffer, flow cell 1 Running buffer 
Running buffer, flow cell 2 Running buffer 
Running buffer, flow cell 3 Running buffer 
Running buffer, flow cell 4 Running buffer 
Sample type High-performance kinetics 
Flow rate 30 µl/min 
Sample contact period 180 s 
Dissociation period 180 s 
Extra wash, flow cell 1 50 % DMSO 
Extra wash, flow cell 2 50 % DMSO 
Extra wash, flow cell 3 50 % DMSO 
Extra wash, flow cell 4 50 % DMSO 
Stabilization period prior to injection N/A 
Stabilization period following injection 120 s 
Analysis temperature 25°C 
Tray temperature 25°C 
  
PKA positive-control sample (H-89)  
PKA positive-control sample 2 µM H-89 in running buffer 
Flow rate  30 µl/min 
Contact period 180 s 
Dissociation period 180 s 
Extra wash, flow cell 1 50 % DMSO 
Extra wash, flow cell 2 50 % DMSO 
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Extra wash, flow cell 3 50 % DMSO 
Extra wash, flow cell 4 50 % DMSO 
Stabilization period prior to injection N/A 
Stabilization period following injection 120 s 
Analysis temperature 25°C 
Tray temperature 25°C 
Positive-control samples for CA (furose-
mide) 
 
Positive-control carbonic anhydrase 20 µM furosemide in running buffer 
Flow rate 30 µl/min 
Contact period 180 s 
Dissociation period 180 s 
Extra wash, flow cell 1 50 % DMSO 
Extra wash, flow cell 2 50 % DMSO 
Extra wash, flow cell 3 50 % DMSO 
Extra wash, flow cell 4 50 % DMSO 
Stabilization period before injection N/A 
Stabilization period after injection 120 s 
Analysis temperature 25°C 
Tray temperature 25°C 
Negative-control samples for PKA and CA  
Negative-control sample Running buffer 
Flow rate 30 µl/min 
Contact period 180 s 
Dissociation period 180 s 
Extra wash, flow cell 1 50 % DMSO 
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Extra wash, flow cell 2 50 % DMSO 
Extra wash, flow cell 3 50 % DMSO 
Extra wash, flow cell 4 50 % DMSO 
Stabilization period prior to injection N/A 
Stabilization period following injection 120 s 
Analysis temperature 25°C 
Tray temperature 25°C 
Solvent correction  
Solvent correction employing DMSO Running buffer having DMSO-concentra-
tions ranging from 1.2 % to 2.6 % in eight 
increments of 0.2 % 
Flow rate 30 µl/min 
Contact period 180 s 
Dissociation period 180 s 
Stabilization period prior to injection N/A 
Stabilization period following injection 120 s 
Analysis temperature 25°C 
Tray temperature 25°C 
Regeneration  
Regeneration solution 1, flow cell 1 100 mM NaHCO3, pH: 8.7 
Regeneration solution 1, flow cell 2 100 mM NaHCO3, pH: 8.7 
Regeneration solution 1, flow cell 3 100 mM NaHCO3, pH: 8.7 
Regeneration solution 1, flow cell 4 100 mM NaHCO3, pH: 8.7 
Contact period 30 s 
Stabilization period following injection 120 s 
 
56 
  
DMSO solvent-correction samples and positive/negative-control samples were injected at 
intervals of ten compound-injection cycles, for both PKA and for CA. 
 
2.2.2.3. FRAGMENT-HIT CHARACTERIZATION 
Fragment-binding steady-state equilibrium may be assessed using the Langmuir adsorption 
isotherm. The data from the titration curves obtained during hit characterization are fit to the 
Langmuir isotherm binding model via a nonlinear regression analysis, yielding the values of 
KD, Rmax, and the offsets, which are related by 
 
     
(Eq. 6) 
 
The titration series employed in hit characterization was prepared such that it would cover the 
expected range of fragment binding affinities. The titration series thus included fragment 
concentrations ranging from 1 mM, down to approximately 1 µM. 
 
Titration series involving ten fragment concentrations were prepared. Stock solutions having a 
compound concentration of 100 mM were prepared by dissolving solid fragment in 100 % 
DMSO, followed by dilution to 50 mM fragment, 100 % DMSO, in Eppendorf tubes. The 
compounds were then diluted in sample-preparation buffer to a 1-mM fragment concentration 
in 2 % DMSO. The compound-buffer solution was vortexed for 5 seconds in a VWR 
International vortexer and followed by centrifugation for one minute at 6,000 g in an 
Eppendorf 5415D centrifuge. 
 
Fragment concentrations were prepared via 1:1-dilutions in ten increments (1 mM, 500 µM, 
250 µM, 125 µM, 62.5 µM, 31.25 µM, 15.625 µM, 7.8125 µM, 3.90625 µM, and 
1.953125 µM). The compound solutions were transferred from the Eppendorf tubes to 
BIACORE 386 well plates. The plates were then sealed using BIACORE sealing film pending 
usage.  
 
Running buffer, DMSO-correction samples, positive/negative-control samples and surface-
regeneration conditioner were prepared, following the same method employed in the case of 
SPR-screening. 
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SPR- data analysis 
 
Fragment binding curves were investigated using BIACORE A-100 evaluation software. 
Fragment screening data was assessed by following the BIACORE A-100 evaluation 
software’s presettings. Assessments of fragment-hit characterizations were conducted by 
following the BIACORE A-100 evaluation software’s presettings. Data analysis employed 
affinity-computation and sensorgram-visualization tools. The data was fit to the Langmuir 
binding isotherm, assuming a 1:1-binding model, which yielded the values of KD, Rmax, and 
the offsets for the fragments employed in hit characterization. 
2.2.3. BIOCHEMICAL ASSAYS AT HIGH FRAGMENT CONCENTRATIONS 
Employment of high compound concentrations in biochemical assays in order to allow 
identifying weakly binding fragments represents a further screening option for finding binders 
and involves extending the concentration range of a typical primary biochemical assay up to 
the mid-µM or high-µM ranges. Lessened assay volumes and the concomitant decreases in the 
quantities of biological reagents required are perceived as key factors that have improved the 
utility of biochemical assays in both HTS and FBLD. 
 
HCA-approaches typically employ the same biochemical assays employed for screening 
larger-molecule compounds having greater affinities, but are conducted at higher substance 
concentrations. Fluorescence readout or radioisotope readout are assay techniques that are 
typically employed in HCA. The major advantages of HCA in FBLD are that the assays 
involved yield high throughput rates, are, in principle, quantitative, and utilize widely 
available technologies for detection. 
 
However, pitfalls also arise when utilizing HCA in FBLD. Both false positives and false nega-
tives can occur. For instance, added-fragment concentrations might interfere with the assays 
via unwanted mechanisms. Prospective causes of problems include compound interference, 
e.g., fluorescence quenching and/or fluorescence, with assay readout and “nonspecific” 
binding to, or disruption of, the target protein, or to enzymes causing jumps in signal 
amplitude. False negatives due to the effective lack of compound solubilities can also occur. 
 
Noteworthy is that there are a number of reports in the literature where fragment molecules 
have been identified by biochemical assays conducted at high compound concentrations, and, 
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since high-throughput screening devices are employed, FBLD-studies employing HCA-meth-
ods are subject to virtually no limitations on throughput rates, which will allow conducting 
more extensive explorations of the diversities of fragment chemical spaces.  
 
PKA biochemical assays 
MerckSerono’s in-house Assay Department was commissioned to setup and run the high-
compound-concentration biochemical assays (HCA) involved. In brief, the HCA-fragment 
screening conducted employed a fragment concentration of 100 µM and runs were set up as 
competition experiments involving an ATP-concentration of 20 µM. 
 
PKA was diluted to 5 mU – 20 mU in 20-mM MOPS at a pH of 7.5, 1 mM EDTA, 0.01 % 
Brij35, 0.1 % b-mercaptoethanol, and 1 mg/ml BSA. PKA was assayed against the Kemptide 
oligopeptide (LRRASLG) in a final volume of 25.5 μl containing 8 mM MOPS at a pH of 7.5, 
0.2 mM EDTA, 30 μM substrate peptide, 10 mM magnesium acetate, and 0.005 mM 
[33Pg-ATP] (50 cpm/mole – 1,000 cpm/pmole). 0.5 µl compound in DMSO-solution was 
added and the mixture incubated for 30 minutes at room temperature. Assays were stopped by 
adding 5 μl 0.5-M (3 %) orthophosphoric acid and their results harvested onto P81 Unifilter 
plates employing a wash buffer of 50 mM orthophosphoric acid. Compound concentrations 
ranged from 200 µM down to 7 nM at the hit-characterization stage. IC50-values were 
determined following fitting of the inhibition data to a 1:1-binding model. 
 
Protein (PKA) 20 mM MOPS 
pH: 7.5 
0.01 % Brij35 
1 mM EDTA 
0.1 % b-mercaptoethanol 
1 mg/ml BSA 
Substrate 30 µM Kemptide (LRRASLG) peptide 
8 mM MOPS  
pH: 7.5  
0.2 mM EDTA  
10 mM magnesium acetate 
0.005 mM [33Pg-ATP] (50-1000 cpm/pmole)  
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30 min 
25°C 
Compounds Titration series covering the range 200 µM to 
7 nM 
Assay-stop solution 5 μl of 0.5 M (3 %) orthophosphoric acid  
Harvesting onto P81 Unifilter plates  
Wash buffer: 50 mM orthophosphoric acid. 
 
2.2.4. FRAGMENT-LIBRARY DESIGN 
The molecules listed in fragment libraries are employed in various screening and characteriza-
tion methods in order to detect and characterize fragments’ interactions with target proteins. 
Fragment libraries have been designed to assemble sets of molecules that should be included 
therein. A molecular weight of less than 300 Da is regarded as the cutoff point for fragments 
(Congreve, et al., 2003). Examples of the other molecular parameters involved are the number 
of hydrogen bond donors and acceptors, as well as the solubilities of the fragments at the 
concentration ranges employed. Several studies and approaches have been employed in 
designing fragment libraries. Two different fragment libraries have been utilized in the pair of 
studies reported in this dissertation. A protein-kinase-targeted library was designed for the 
screening setup involving SPR, HCA, and protein crystallography. In the case of the other 
study involved, the associated fragment library was configured following a screening of the 
in-house database for fragments that had exhibited activities with respect to PKA in previous 
assays. Ready fragment availability was another parameter employed in assembling that 
fragment library.  
 
The protein-kinase-targeted-fragment library was designed using the ZINC database and 
MerckSerono’s in-house library-design and computational tools. The ZINC database (UCSF, 
http://zinc.docking.org/) was utilized and the following fragment-defining variables applied. 
The settings employed were in compliance with the rule of three (Congreve, et al., 2003). 
• 100 Da ≤ molecular weight ≤ 300  
• clogP ≤ 3 
• HBA ≤ 3  
• HBD ≤ 3  
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• NROT ≤ 3  
• PSA ≤ 60  
• Deliverable within one to three weeks 
 
A computed solubility (clogs, pH 7.4) of 200 µM that was assigned using MerckSerono’s in-
house solubility-computation tool was employed as a further criterion. The fragment library 
was exported in the form of sd-files. The fragments involved were manually surveyed using 
ISIS Base and Accord for Excel for visualizing the structures contained in the sd-files. 
Fragments for a protein-kinase targeted-chemical library were selected using the “chemical 
eye” gained from first-hand experience. Fragments containing one or more atoms that 
theoretically are capable of interacting with the donor-acceptor-donor moiety available in the 
hinge zone were selected. MerckSerono’s in-house database tools were utilized for checking 
the availability of the compounds involved in MerckSerono’s compound-storage facility. The 
final library contained all fragment compounds that were available in 10-mM concentrations 
in 100 % DMSO and packaged in vials containing 30 µl per vial. At least five vials were 
available per compound. 
 
The fragment library based on selections of reported interaction data was assembled following 
a filtering of MerckSerono’s in-house database. That compound database was screened using 
ISIS Base and the following parameter set: 
• Molecular weight ≤ 300 Da  
• Computed solubility at pH 7.4 (clogs, pH 7.4) ≥ 2 x 10-4 M 
• PKA-inhibition ≥ 50 % at 10-µM fragment concentration 
• Availability of the compound in solid from MerckSerono’s in-house compound-
storage facility 
 
Crystallization scaffolds were selected by the manual “chemical eye” method such that one 
example of each chemical scaffold was represented. Compounds listed in the library were 
stored in an ISIS Base database. An sdf-file containing the compounds selected and their 
properties was prepared using Accord for Excel and exported as a csv-file that was imported 
into the SpotFire program employed for keeping track of the fragments and the empirical data. 
Fragments listed in the library were ordered from in-house databases for delivery within 24 
hours prior to commencement of the experimentation. 
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Library-generation and virtual-screening 
software 
ZINC (UCSF, http://zinc.docking.org/)  
ISIS Base (MDL Information Systems, Inc.) 
ISIS Draw (MDL Information Systems, Inc.) 
Accord for Excel (Accelrys, Inc.) 
MOE (Chemical Computing Group, Inc.) 
SpotFire (Tibco Software, Inc.) 
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Chapter 3  
RESULTS 
 
 
3.1. FBLD INVOLVING SPR, HCA, AND PROTEIN CRYSTALLOGRAPHY 
Under the approach to FBLD involved here, three different techniques were utilized for 
investigating fragment-protein interactions, surface-plasmon-resonance (SPR) analyses, high-
compound-concentration biochemical assays (HCA) and protein crystallography. The 
outcomes of those investigations are presented below. 
3.1.1. RESULTS OF SURFACE-PLASMON-RESONANCE (SPR) ANALYSES 
Immobilization of PKA on the sensor chip’s surface was the initial stage of SPR. Carbonic 
anhydrase II (CA) was also immobilized thereon and employed as a reference protein. 
Immobilization was carried out using an amine-coupling procedure. Immobilization of PKA 
resulted in three protein-density levels. The response units for each level were approximately 
3,000 RU, 6,000 RU and 10,000 RU. The response-unit level for CA-immobilization was 
approximately 2,000 RU.  
 
Injections of positive-control compound revealed protein activity levels. H-89 was employed 
as a positive control in the case of PKA, and furosemide was employed as a positive control in 
the case of CA. Protein activity levels were assigned under the assumption that the positive 
control compounds underwent 1:1-stoichiometry interactions with the protein 
    
(Eq. 4) 
Both PKA and CA exhibited an activity level of approximately 100 %. Fig.13 depicts the 
sensorgrams obtained from injecting the positive-control compounds onto the surfaces of 
PKA and CA. 
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Fig.13. Sensorgrams for the positive-control samples employed in screening and hit characterization. 
These sensorgrams illustrate the binding of H-89 to PKA and furosemide to CA. Both positive-control 
compounds were applied in concentrations that saturated the protein’s surface. Saturation was exhibited in the 
form of an abrupt increase in response following the start of injections in the case of both H-89 and furosemide. 
 
Control compounds were injected at intervals of ten fragment-injection cycles during 
screening runs. Surface activity was maintained during screenings in all but one case, where a 
single fragment remained attached to the protein’s surface following an injection cycle (cf. 
Fig.17 C), which resulted in a lower PKA activity level, and thus reduced responses from 
those fragments binding to the surface involved during subsequent injection cycles. New PKA 
activity levels were assigned to that surface employing the results of subsequent PKA 
positive-control-compound runs, which allowed conducting an analysis of all screening data. 
 
Maximum response levels, Rmax, were employed in assigning cutoff levels to the maximum 
responses correlated to 1:1, fragment-protein interactions during screening. Those cutoff 
levels were computed from the associated immobilized-protein level, protein activity level, 
the molecular weight of the fragment involved, and the protein’s molecular weight (cf. Eq. 4). 
The SPR-evaluation software was utilized for normalizing fragment responses, expressed in 
RU, referred to the molecular weight of each fragment involved, which resulted in maximum 
responses of 30 RU for 1:1, fragment-protein binding during the screening of the 
257 fragments involved. However, injections of the negative-control samples indicated that 
variations from the baseline were occurring on the screening setup employed and assigned a 
lesser cutoff level to detection of fragment binding to low-density PKA-surfaces (those having 
3,000-RU immobilized PKA; spot 1 on the sensor chip) during screening, which yielded a 
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lower cutoff level of 5 RU. Calibration runs employing solvent/DMSO-concentrations 
ranging from 1.2 % to 2.8 % were employed for correcting for larger mismatches in binding 
signals caused by variations in DMSO-concentration from sample to sample. Those solvent 
corrections were applied to all fragments investigated under the screening runs. 
 
The 257 fragments were injected across all flow cells and detection areas at a fragment 
concentration of 200 µM. Fig.14 presents an overview of the results obtained from screening 
the 257 fragments, where the high and low cutoff levels for fragment binding are shown. The 
green spots represent fragments whose binding responses, expressed in RU, fell within the 
range stipulated for 1:1-interactions. The blue spots represent fragments that failed to exhibit 
responses exceeding the lower cutoff level. The red spots represent fragments whose 
responses exceeded that for 1:1 fragment binding, which might indicate either their bonding to 
multiple sites or a nonspecific binding of fragment aggregates to the protein. The full set of 
screening results is presented in Appendix 1. 
 
 
Fig.14. A plot of the responses obtained from fragment screenings. The plot provides an overview of the 
responses of all 257 fragments screened and has been prepared using BIACORE A-100 evaluation software. 
Response amplitudes for all 257 fragments are plotted versus cycle numbers and have been adjusted to allow for 
molecular weight. The upper and lower cutoff levels are indicated by the horizontal lines. The green spots 
represent fragments whose binding responses fell within the range for 1:1-interactions. The blue spots represent 
fragments whose responses failed to exceed the lower cutoff level of 5 RU. The red spots represent fragments 
whose responses indicate superstoichiometric fragment-protein interactions. The 60 hits were selected from 
among the green spots following manual inspections of their sensorgrams. 
 
Fragments that exhibited binding responses falling between the high and low cutoff levels 
were manually investigated. The fragment concentration employed in the screenings 
(200 µM) resulted in transient binding responses from most fragments. Fragment responses 
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classified as hits were thus confined to those fragments whose sensorgrams exhibited such 
typical fragment-binding responses (cf. Fig.16).  
 
SPR-responses are proportional to the changes in molecular weight occurring when fragments 
bond to the protein’s surface. A further requirement for classification as a hit was that 
responses should be proportional to the quantities of immobilized PKA. There thus should be 
a rise in response correlated to binding on surfaces having higher immobilized-protein 
densities, and that was the case for all fragments classified as hits under the screenings 
conducted (cf. Fig.16).  
 
The SPR sensor chip employed utilizes a reference surface, on which the protein carbonic 
anhydrase II (CA) was immobilized. Screenings detected eleven fragments that interacted 
with both PKA and CA. Those fragment interactions were excluded from further characteriza-
tion. Fig.15 depicts the sensorgrams of a fragment that interacted with both PKA and CA. 
 
 
Fig.15. Sensorgrams of a fragment that interacted with both PKA and CA. A comparison of the response 
curves for PKA and CA indicates that the fragment involved bonded to the surfaces of both PKA and CA. Such 
fragments were not classified as hits under the screenings conducted. 
 
The criteria for classification as a hit are listed in Table 4. Application of those criteria 
resulted in 60 fragments being classified as hits under the screenings conducted. The 
sensorgram of a fragment that met those criteria is illustrated in Fig.16.  
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Table 4. Criteria for SPR fragment screening hit selection. The table below lists the criteria for classifying 
fragments as hits in conjunction with the screenings conducted. The upper cutoff level was set to 30 RU and the 
lower to 5 RU. Increases in binding response varying with protein density/immobilization levels were also 
required. The binding sensorgrams should resemble those typical of transient fragment binding. A fifth criterion 
was specificity in binding to PKA.  
Fragment hit-classification criteria Remarks 
Binding responses exceeding a lower cutoff 
level, where a response of > 5 RU was 
interpreted as indicating binding to the 
surface of low-density PKA 
Assignments of signal/noise ratios based on the results 
obtained from injecting negative-control samples yielded a 
lower cutoff level of 5 RU. 
Binding responses remaining below an 
upper cutoff level, Req, of < 2 Rmax 
Rmax, which corresponded to 30 RU in the case of low-density 
PKA-surfaces, should not be exceeded by more than a factor of 
two 
Transient binding responses All fragments classified as hits should exhibit typical transient 
binding.  
Binding responses proportional to immob-
ilized PKA-densities 
Responses due to binding to higher-density protein surfaces 
should exceed those for binding to lower-density protein 
surfaces. 
Specificity for binding to PKA All hit-fragments should exhibit specific binding to PKA. Frag-
ments binding to the reference protein, CA, were rejected.  
 
 
Fig.16. Sensorgrams of a typical hit-fragment. Illustrated above are the sensorgrams obtained from a single 
flow cell following injections of solutions having a 200-µM fragment concentration across all five spots. All 
responses have been corrected to allow for the solvents, molecular weights, and reference levels involved. The 
fragment in question exhibited transient binding. No binding to the surface of CA was observed. Its responses 
increased with increasing density of the immobilized protein. Its response on the 3k PKA-surface never fell 
below 5 RU and never exceeded 30 RU, and thus remained between the upper and lower cutoff levels. 
 
The sensorgrams obtained from the screenings revealed several fragments whose binding 
failed to correspond to a 1:1-stoichiometry binding model. Such fragments bind in a manner 
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that has been termed “promiscuous binding” in the SPR-literature (Gianetti, et al., 2008). 
Forty-five of the 257 fragments exhibited binding responses indicative of promiscuous 
binding and were identified by manual examinations of the sensorgrams. Three examples of 
such sensorgrams are shown in Fig.17 
 
A 
 
B 
 
C 
 
Fig.17. Sensorgrams of fragments exhibiting promiscuous binding. Sensorgrams from the screenings, 
illustrating the responses of fragments exhibiting promiscuous binding. (A) Although the fragment involved 
yielded responses that remained between the upper and lower cutoff levels, it failed to exhibit any responses 
similar to typical transient binding. Such binding responses have been reported in the case of micelles that 
interact with the protein. (B) The sensorgrams resulting from fragment injection cannot be characterized as 
indicative of any particular mode of interaction. The interactions involved were therefore nonspecific and 
similar to those with the surfaces of CA and PKA. (C) Fragment injection resulted in superstoichiometric 
interactions with the protein. The fragment adhered to the protein’s surface in a pseudo-irreversible manner, 
resulting in an escalating baseline. 
 
Examinations of the sensorgrams for all 45 fragments involved facilitated classifying 
promiscuous binding responses, based on the nomenclature proposed by Gianetti and Huber 
(Gianetti, et al., 2008; Huber, 2005). The various types of promiscuous binding occurring in 
the sensorgrams shown in Fig.17 were suggestive of either binding of micelles (A), binding of 
fragments suffering from solubility problems (B), or binding of fragment aggregates that 
failed to detach from the protein’s surface during the dissociation phase (C). 
 
Those fragment aggregates that failed to detach from the protein’s surface once injection had 
ceased were detached using regeneration conditioner. NaHCO3 regeneration conditioner 
having a pH of 8.5 detached all such aggregates, except those whose sensorgrams are shown 
in Fig.17C, from its surface.  
 
The 68 screening hits were subsequently characterized employing series of graduated frag-
ment concentrations. All of the hits involved were characterized, based on both SPR and 
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HCA. In the case of SPR, the fragment concentrations employed ranged from 1 mM to 
approximately 1 µM, while for HCA, they ranged from 200 µM to approximately 1 nM. The 
responses obtained from SPR-hit characterizations facilitated classifying the 68 fragments into 
five subgroups. The subgroups and various types of fragment characteristics involved shall be 
described below and are summarized in Fig.18.  
 
 
Fig.18. The results of SPR-hit characterizations. SPR-hit characterizations involved fragment concentrations 
ranging from 1 mM to 1 µM. The fragments involved were classified into various groups, based on their binding 
responses. Twenty-four fragments exhibited typical transient binding responses and their affinity constants, KD, 
were computed. Another 24 fragments exhibited transient binding responses, but no affinity constants were 
computed for them. Nine fragments exhibited binding similar to that termed “promiscuous binding” (Gianetti, et 
al., 2008) and eight fragments exhibited binding behaviors indicating that concentration-dependent aggregations 
were occurring. Nine fragments exhibited binding responses that remained below the lower cutoff level. 
 
Fragments that had exhibited transient binding responses and whose affinities had been 
computed were classified as “typical transient-binding, estimated-affinity” fragments (Group I 
fragments). Fragments exhibiting transient binding, to which no 1:1-binding models or 
affinities, KD, were assigned, were classified as “typical transient-binding, no-estimated-
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affinity” fragments (Group II fragments). The third group consisted of those fragments whose 
responses could not be correlated to any 1:1, fragment-protein-interaction models. Such 
fragments were classified as “fragments exhibiting promiscuous binding” (Group III 
fragments). Further, those fragments that had exhibited transient, 1:1, binding responses at the 
lower concentrations, but exhibited nonstoichiometric, or promiscuous, binding responses at 
the higher concentrations, were classified as “fragments subject to concentration-dependent 
effects” (Group IV fragments). Sensorgrams similar to those of Group III and Group IV 
fragments had earlier been described by Huber (2006) and Gianetti, et al. (2008). Finally, 
fragments that exhibited binding responses that failed to exceed the lower cutoff level were 
classified as “nonbinders” (Group V fragments).  
 
Fig.19 depicts the sensorgrams of a fragment that was allocated to Group I, since they are 
typical of transient fragment binding. The occupancies of protein binding sites increased with 
fragment concentration. A plot of its binding responses versus fragment concentration yielded 
a curve that asymptotically approaches unity (cf. Fig.19). In the case of such fragments, fitting 
their response data to the Langmuir-isotherm model yielded the values of their equilibrium 
binding constant (KD), Rmax, and offset. Equilibrium binding constants (affinities) were 
computed for 24 of the 68 fragments included in the hit characterizations. All 24 selectively 
interacted with the PKA’s surface and exhibited either no, or only very low, responses due to 
interactions with the CA’s surface. 
 
(A) Group I fragment 
 
(B) Response-concentration curve for fragment 6 
Fig.19. An example of a fragment that exhibited transient binding and was assigned an estimated affinity 
(Group I fragment). (A) Sensorgrams from the series involving graduated fragment concentrations exhibit the 
flat response curves indicating that typical transient binding was occurring. (B) A plot of its binding responses 
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versus fragment concentration yielded a curve that asymptotically approaches unity. The data have been fit to the 
Langmuir-isotherm binding model employing a nonlinear-regression analysis that yielded the values of KD, Rmax, 
and the offset. 
 
Group II contained 24 fragments. Although they exhibited typical transient binding, their 
responses exceeded those expected for 1:1, fragment-protein interactions, and no saturation of 
protein binding sites was observed for them. Since it proved impossible to fit the data to a 
1:1-binding model in the case of those fragments involved, no affinities were computed for 
them. Sample sensorgrams for a fragment from that group are shown in Fig.20.  
 
(A) Group II fragment 
 
(B) Response-concentration curve for fragment 22 
 
Fig.20. Sensorgrams for a fragment exhi ting transient binding, but for which no KD was computed. 
roup III consisted of fragments exhibiting nonspecific protein interactions. McGovern, et al. 
bi
Although the fragment involved yielded sensorgrams typical of transient binding, the Rmax expected for 1:1, 
fragment-protein interactions was exceeded. Since saturation of protein binding sites failed to occur, binding 
isotherms could not be employed for computing such fragments’ affinities (KD). 
 
G
(2008) and Gianetti, et al. (2008) had also proposed that the occurrence of such nonspecific 
interactions should result in the fragments involved being classified as promiscuous binders. 
Another nine fragments were added to Group III following hit-characterization runs. Two 
examples of sensorgrams obtained from those runs are shown in Fig.21, where (A) depicts 
those for a fragment classified in this dissertation as exhibiting “general promiscuous 
binding,” i.e., to which no particular mode of fragment-protein interaction could be assigned, 
which meant that their sensorgrams could not be utilized for deriving affinity constants. The 
sensorgrams obtained for another fragment classified as belonging to Group III are shown in 
Fig.21 (B). Although its binding responses were typical of transient binding, Rmax was 
exceeded by more than a factor of two, indicating occurrence of a class of interactions that has 
been termed “nonstoichiometric binding.” One possible explanation of that sort of behavior is 
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) Group III (general promiscuous 
that such fragments form oligomers or aggregates that undergo transient interactions with the 
protein involved.  
 
(A (B) Group III (nonstoichiometric binding) 
 
binders) 
 
Fig.21. Sensorgrams of fragments exhibiting promiscuous binding. (A) Sensorgrams of a fragment classified 
related any particular m de of 
 type of response curve that has been described by Gianetti, et al. (2008) as being associated 
as exhibiting general promiscuous binding. Such sensorgrams cannot be cor
fragment-protein interaction. (B) Although the fragment’s sensorgrams are typical of transient binding, some of 
its response curves exceeded Rmax by more than a factor of two. Its interaction stoichiometry therefore fails to 
correspond to that of a 1:1-interaction model. This particular fragment is an example of fragments that exhibited 
nonstoichiometric binding in conjunction with hit characterizations. 
 
o
A
with large aggregates that bind to the protein was observed in the case of three fragments 
included in the hit characterizations conducted. Such “superstoichiometric binders” yield 
responses that exceed the maximum for 1:1-interactions by more than a factor of five and 
have been assigned to a subgroup of promiscuous binders that have been classified as 
members of Group III. Fig.22 depicts the sensorgrams obtained for one such 
superstoichiometric binder. 
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Group III  (superstoichiometric binders); 
the case of fragment 100 
Fig.22. Sensorgrams of a 
superstoichiometric 
binder. Fragment binding 
response exceeded that 
expected for a 1:1, frag-
ment-protein, interaction 
model (Rmax) by more 
than a factor of five. Such 
strong binding to the 
PKA’s surface is termed 
“superstoichiometric pro-
miscuous binding.” Such 
response curves have 
been correlated to large 
fragment aggregates that 
interact with the protein 
involved. 
 
The SPR-runs conducted covered the association and dissociation phases of the molecular 
interactions involved, which allowed assessing their reversibilities. The data obtained allowed 
identifying another subgroup of Group III. That subgroup consisted of those fragments that 
failed to dissociate from the protein following the conclusions of injection phases. Such 
interactions are termed “irreversible-binding interactions” or “pseudo-irreversible binding 
interactions.” The hit-characterization runs conducted turned up four fragments exhibiting 
irreversible or pseudo-irreversible binding. The sensorgrams of one such fragment are shown 
in Fig.23. 
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Group III (pseudo-irreversible binders); 
the case of fragment 74 
Fig.23. Sensorgrams of a 
fragment undergoing pseu-
do-irreversible binding to 
the protein involved. Its 
sensorgrams indicate that 
fragment aggregates form 
and bond to the PKA’s 
surface. Those fragment 
aggregates that have formed 
also accumulated on the pro-
tein’s surface, which is 
reflected in an escalating 
baseline that continues to 
escalate following the 
surface-regeneration stage. 
 
Further investigation of the results of hit-characterization runs turned up a distinct, fourth 
group consisting of eight fragments that exhibited behaviors indicative of the occurrence of 
concentration-dependent effects. Although the fragments involved exhibited no signs of 
promiscuous or superstoichiometric binding at the lower compound concentrations, the higher 
compound concentration yielded either responses that exceeded those expected for the case of 
1:1-interactions with the proteins involved or sensorgrams that could not be correlated to 
1:1-interactions with them. A closer examination of those fragments showed that they 
exhibited 1:1-binding behavior with the PKA’s surface at the lower compound concentrations. 
The fragments involved exhibited behaviors similar to those of fragments that were classified 
by Gianetti, et al. (2008) as belonging to the group subject to “concentration-dependent 
effects.” Nevertheless, in this dissertation, Group IV is defined as consisting of all those 
fragments exhibiting irregular, concentration-dependent, sensorgrams. The sensorgrams of a 
fragment subject to concentration-dependent effects are presented in Fig.24. 
74 
  
 
Group IV (fragments exhibiting concentration-dependent aggregation); 
the case of fragment 19 
Fig.24. Sensorgrams of a fragment exhibiting concentration-dependent aggregation. Its hit-characterization 
sensorgrams indicate that it interacts with the protein in accordance with a 1:1-binding model at the lower 
compound concentrations. However, once compound concentration exceeds 32 µM (the purple curve), the 
fragment involved starts forming aggregates that exhibit promiscuous binding to the protein. The titration series 
therefore classifies the fragment as exhibiting concentration-dependent aggregation. 
 
The fifth group consisted of nine fragments whose sensorgrams failed to indicate binding 
responses exceeding the lower cutoff level of 5 RU. 
 
3.1.2. HIGH-COMPOUND-CONCENTRATION BIOCHEMICAL ASSAYS 
Inhibition of PKA-substrate phosphorylation was investigated by means of biochemical-assay 
screenings at a fragment concentration of 100 µM. The lower cutoff for classification as hits 
was set to 30 % inhibition. The biochemical-assay screenings conducted resulted in 26 of the 
total of 257 fragments being classified as capable of inhibiting PKA. The percentage 
inhibitions of all 257 fragments are listed in Appendix 1. The hit characterizations performed 
subsequent to the SPR/HCA-screenings yielded the variations in their PKA-inhibitions with 
concentration, which were deduced from the results of series of runs employing graduated 
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concentrations (MerckSerono’s in-house Assay Department was commissioned to conduct 
that work). The data obtained were fit to a 1:1-binding model and the inhibition constants, 
IC50, of the various fragments computed. The HCA hit characterizations resulted in the 
determination of twelve IC50-values (cf. Appendix 1). Fig.25 depicts the activity curves for 
two of the fragments involved, based on a 1:1-binding model.  
 
(A) (B) 
Fig.25. HCA hit-characterization data for two fragments. Activity curves for two sample fragments obtained 
from the series of graduated-concentration runs conducted in conjunction with hit characterizations, where the 
y-axis represents the percentage inhibition of PKA-substrate phosphorylation on the x-axis represents the 
logarithm of fragment concentration, expressed in µM. Fragment concentration ranged from 200 µM to 7 nM. 
HCA hit characterization was applied to all 68 screening hits and resulted in twelve IC50-values covering the 
affinity range 23 µM to 110 µM. 
 
3.1.3. PROTEIN CRYSTALLOGRAPHY 
The complexes that fragments formed with PKA involved the recombinant, catalytic subunit 
of cyclic, AMP-dependent, protein kinase (PKA) and the pseudosubstrate, kinase-inhibiting 
peptide [PKI(5-24)]. All crystals were crystallized in the orthorhombic space group P212121. 
Similar cell constants of around 72 Å, 78 Å, and 80 Å were observed for all crystals. Except 
for those variations in protein conformation reported in the results section of this dissertation, 
no major structure variations in PKA-conformations were noted. The conformations of PKA’s 
small lobe and large lobe were relatively rigid. Structure patterns, such as the DFG-motif, 
C-helix, and activation loops, were also evident in earlier reports on the conformations of its 
crystalline structures. 
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Structure determinations employing protein crystallography were attempted for the 68 hits 
resulting from both the HCA-screenings and SPR-screenings. In the case of nine hits, the 
structures of the fragment-PKA complexes involved were determined. Table 5 presents an 
overview of the protein-crystallography studies conducted under the present approach to 
FBLD. 
 
Table 5. An overview of the protein-crystallography studies conducted under the present approach to 
FBLD. The 68 hits from SPR/HCA-screenings were analyzed employing protein crystallography in an initial 
round in order to determine the modes, by which fragments bond to PKA, which resulted in determinations of 
the 3D-binding modes of six fragments. The second round of protein-crystallographic analyses involved only 
those fragments whose affinities or inhibition constants had been determined, but failed to yield the structures of 
any new, crystalline, fragment-protein complexes. The third round included further optimizations of the protein-
crystallographic conditions and resulted in identification of another three structures involving 3D-fragment-
protein interactions. 
 
 
 
Following the initial soaking, around six fragment-PKA structures were derived from the 
results of protein crystallography. The fragments involved were unambiguously detected in 
the electron densities of the ATP binding sites on PKA. Twenty-one soaking attempts resulted 
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in crystal instabilities. The protein crystals involved either lost their diffractive properties or 
immediately dissolved upon soaking.  
 
Under the second round, crosslinking with gluteraldehyde was employed for stabilizing the 
protein crystals, which allowed employing those fragment soakings that had resulted in crystal 
instabilities and loss of diffractive properties under the initial round for collecting X-ray data. 
However, all soakings resulted in incidence of vacant binding sites during the second round.  
 
Extended soaking periods, higher fragment and DMSO concentrations, and cocrystallization 
were employed in the third round and the structures of another three fragment-protein 
complexes were derived. The detailed results for all nine fragments are presented in Table 10, 
which has been relegated to Appendix 2. 
 
The structures revealed that all nine fragments bound in the ATP binding pocket of PKA 
(Fig.26). Table 10, which appears in Appendix 2, includes graphic representations of the 
fragment binding modes involved and discusses the associated interactions. 
 
Fig.26. The binding modes of the nine hit-fragments to PKA. The diagram shows the ATP-pocket in PKA, 
overlain with the binding modes of the nine hit-fragments. 
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3.1.4. PRESENTATION OF SELECTED RESULTS 
Under the present approach, a library of 257 fragments was screened for binders employing 
SPR and HCA. Sixty-eight of those fragments were classified as hits following screening, 60 
of which were turned up by the SPR-runs, and 26 of which were turned up by the HCA-runs. 
Eighteen hits thus resulted from both screening assays. Selection of the 26 hits resulting from 
the HCA-runs followed a 100-µM-concentration screening, where only those fragments that 
inhibited PKA-substrate phosphorylation by at least 30 % were classified as hits.  
 
A characterization of those hits was subsequently conducted in order to allow further analyses 
of their interactions with the protein. Affinity constants, KD, and inhibition constants were 
computed for 28 fragments and 24 affinity constants, KD, were derived from the SPR-data, 
while the IC50-values for twelve fragments were derived from the HCA-data. Values of both 
IC50 and KD were obtained for eight fragments. The KD-values obtained ranged from 15 µM 
to approximately 1 mM, and the IC50-values obtained ranged from 23 µM to 110 µM. Protein 
crystallography yielded the structures of the complexes formed by six of the twelve fragments 
that had yielded a value for IC50. X-ray diffraction yielded the structures of the complexes 
formed by seven of the 24 fragments that had yielded a value for KD. All nine fragments 
forming complexes whose structures had been determined from the results of the X-ray-
diffraction runs had yielded values of either IC50 or KD, or both. 
 
The results of the first approach, which illustrate the similarities and differences between the 
various fragments involved and the experimental methods employed under the present 
approach to FBLD, will be presented below and are summarized in Table 6. 
 
Table 6. Selective interactions observed in conjunction with screenings. Fragment 6 was classified as a hit 
under the SPR-screenings, but not under the HCA-screenings. The electron density derived from protein 
crystallography revealed its 3D-binding mode. Fragment 19 was classified as a hit under the HCA-screenings, 
but failed to exhibit a binding response under the SPR-screenings, so no structure could be derived for it. 
Although fragment 20 was classified as a hit under the HCA-screenings and yielded a structure for the complex 
formed, the results of the SPR-screenings conducted did not allow classifying it as a hit. In the case of fragment 
57, the results of both the SPR-screenings and the HCA-screenings allowed its classification as a binder over the 
concentration range employed, but the structures of the complexes it formed, if any, could not be determined  
 
Fragment SPR-SCREENINGS HCA-SCREENINGS X-RAY 
Fragment 6 + – + 
Fragment 19 – + – 
Fragment 20 – + + 
Fragment 57 + + – 
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Fragment 6 
 (A) SPR-screening (B) HCA-hit characterization 
(C) SPR-hit characterization KD, 100-µM – 200-µM concentration 
 
(D) X-ray binding mode (E) Binding data in total 
) 
(–) 
 – 200 µM (+) 
ned (+) 
SPR-screenings: binder (+
HCA-screenings: nonbinder 
SPR-hit characterization, 100 µM
HCA-hit characterization: nonbinder (–) 
X-ray diffraction: complex-structure obtai
N
N
N
N
N
 
 
Fig.27. Binding data for fragment 6. (A) Fragment 6 met the criteria for classification as a t under the hi
SPR-screenings. (B) Under the HCA-hit characterization runs, it exhibited no significant inhibition of PKA for 
any of the concentrations employed. (C) Its SPR-hit characterization data was fit to the Langmuir binding-
isotherm model and its KD computed. (D) Its binding mode to PKA was determined from protein 
crystallography. (E) The screening and hit-characterization data obtained from the HCA/SPR-screenings. It 
was classified as a hit under both SPR-screening and SPR-hit characterization runs. However, neither the 
HCA-screenings nor the HCA-hit-characterization runs allowed classifying it as a binder/hit. Nevertheless, 
protein crystallography yielded the structure of the complex it formed with PKA. 
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ning 
Fragment 19 
(A) SPR-scree
 
(B) HCA-hit characterization 
 
(C) SPR-hit characterization (D) Binding data  
nbinder (–) 
centration-dependent 
aracterization: nonbinder (–) 
SPR-screenings: no
HCA-screenings: binder (+) 
SPR-hit characterization: con
aggregation; a binder at low concentrations 
(< 32 µM) 
HCA-hit ch
X-ray diffraction: complex-structure indeterminate (–) 
OO
O
 
Fig.28. Binding data for fragment 19. (A) Fragment 19 failed to meet the criteria for classification as a hit 
under the SPR-screenings. Its sensorgrams showed that it exhibited both a typical transient binding response 
and a response that may be classified as promiscuous binding. (B) No significant inhibition of PKA was 
observed under HCA-hit characterization runs, for any of the concentrations employed. (C) Its 
SPR-hit-characterization sensorgrams revealed that it exhibited typical transient fragment binding up to a 
concentration of 32 µM. At concentrations in excess of 32 µM, it exhibited fragment-protein interactions 
similar to those for promiscuous binding and was therefore classified as a fragment forming concentration-
dependent aggregates. (D) A summary of the results obtained from the screenings, hit-characterizations, and X-
ray-diffraction analysis in the case of fragment 19. 
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Fragment 20 
(A) SPR-screenings (B) HCA-hit characterization 
IC50: 51 µM 
(C) SPR-hit characterization 
 
(D) Binding mode from X-ray-diffraction data
 
(E) Binding data 
SPR-screenings: nonbinder (–) 
HCA-screenings: binder (+) 
SPR-hit characterization: binder, but its 
SPR-sensorgrams are difficult to interpret (–) 
HCA-hit characterization: binder (51 µM) (+) 
X-ray diffraction: complex-structure obtained (+) 
N
N
N
N
S
 
 
Fig.29. Binding data for fragment 20. (A) Fragment 20 
failed to meet the criteria for classification as a hit under 
the SPR-screenings. Although its sensorgrams exhibited 
typical transient fragment binding, its responses on the 
PKA-surfaces involved remained below the background-
noise level (5 RU). (B) Inhibition of PKA was observed 
under the HCA-hit-characterization runs conducted at 
concentrations of 70 µM and 200 µM. Its IC50 was 
computed and equaled 51 µM. (C) SPR-hit-
characterization runs yielded responses exceeding the 
lower cutoff and allowed determining its binding mode. 
However, the sensorgrams involved are difficult to 
interpret and KD was not computed for it. (D) Protein 
crystallography allowed determining its 3D-binding mode 
to PKA. 
Fragment 57 
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(A) SPR-screenings 
 
(B) HCA-hit characterization 
IC50: 110 µM 
(C) SPR-hit characterization 
KD: 35 µM 
 
 
 
(D) Binding data 
SPR-screenings: binder (+) 
HCA-screenings: binder (+) 
SPR-hit characterization: binder (35 µM) (+) 
HCA-hit characterization: binder (110 µM) (+) 
X-ray diffraction: complex-structure indeterminate 
(–) 
N
N
N
NN
O
 
Fig.30. Binding data for fragment 57. (A) Frag-
ment 57 met the criteria for classification as a hit under 
the SPR-screenings. (B) Inhibition of PKA was 
observed under the HCA-hit-characterization runs con-
ducted at concentrations of 70 µM and 200 µM. Its IC50 
was computed and equaled 110 µM. (C) Its SPR-hit-
characterization data was fit to the Langmuir binding-
isotherm model and its KD computed and equaled 
25 µM. (D) Protein crystallography failed to yield the 
structures of any complexes that might have formed. 
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3.2. RESULTS OBTAINED BY EMPLOYING AVAILABLE BIOCHEMI-
CAL-ASSAY DATA IN THE PROTEIN-CRYSTALLOGRAPHIC ANALYSES 
MerckSerono’s in-house database was screened for compounds having molecular weights of 
less than 300 Da, computed solubilities exceeding 200 µM, and at least 50 % inhibitions of 
PKA-substrate phosphorylation under biochemical assays involving a fragment concentration 
of 10 µM. All of the compounds involved were available in solid form from MerckSerono’s 
compound-storage facility. That screening yielded a library containing 67 fragments. A subset 
of those 67 fragments was chosen in order to confine further consideration to compounds 
representative of just those chemical scaffolds available among the 67 fragments. That 
selection procedure, which employed the researcher’s “chemical eye,” resulted in 25 frag-
ments being chosen for structure determinations employing protein crystallographic analyses. 
Fig. 31 depicts the chemical structures of seven of those 25 fragments. 
 
 
 
 
Fig.31. Sample fragments selected for protein crystallography. The chemical-structure diagrams of seven of 
the 25 fragments chosen for protein-crystallographic analyses illustrate the wide variety of chemical scaffolds 
found among the 25 fragments involved. 
 
Protein-crystallographic analyses yielded the structures of 21 fragments whose electron densi-
ties indicated binding to PKA. The other four fragments failed to exhibit any evidence that 
they formed complexes with PKA. Table 9 (cf. Appendix 1) presents the results obtained for 
nine of those 21 fragments, along with illustrations of their binding modes to the protein’s 
binding pocket and descriptions of the fragment-protein interactions involved. All 21 frag-
ments interacted with PKA’s ATP binding pocket, which is why the interactions involved 
have been described using the definitions of the ATP-pocket zones proposed by Liao (Liao, 
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2007). Those definitions are listed in Fig.7, which depicts the ATP binding pocket of protein 
kinases and categorizes it into zones designated A, K, R, P, E0, E1, BP-I, and BP-II. 
 
 
ATP-pocket zones defined by Liao 
A Adenosine binding site 
R Ribose binding site 
P Phosphate binding site 
K Catalytic lysine and DFG-motif 
E0 Pocket beneath the A/hinge zones 
E1 Hydrophilic, solvent-exposed pocket 
BP-1 Hydrophobic selectivity pocket 
BP-II Hydrophobic, back-cleft pocket 
 
 
Fig.32. The ATP binding pocket in cAMP-dependent protein-kinase A. An illustration of the zones defined 
by Liao for describing their ATP-pocket. Their designations are listed in the table at right. When ATP binds, the 
adenosine moiety is situated in the A-zone. The ribose is situated in the R-zone. Phosphate groups bind in the 
P-zone. BP-I and BP-II are situated above the A-zone in this view. The K-zone is situated between the A-, R-, 
BP-I-, and BP-II-zones. The E0- and E1-pockets are situated beneath the A- and R-zones, which are described as 
being hydrophilic, solvent-exposed zones. 
 
Table 7. An overview of fragment-protein interactions. Examples of chemical scaffolds detected in each zone 
defined by Liao. The scaffolds stated were observed in the structures of the nine fragment-protein complexes 
described in this dissertation (cf. Appendix 1). The leftmost column lists the symbols assigned to the various 
zones, and the top row lists the nine fragments involved. 
 
 
 Fragment 1 Fragment 2 Fragment 3 Fragment 4 Fragment 5 Fragment 6 Fragment 7 Fragment 8 Fragment 9 
A 
(hinge) 
phenol 
amine-
pyrazole 
pyrazole 
amino-
pyrazole 
pyrazolo-
pyrimidine 
amide pyridine 
chloro-
indole 
amino-
pyrimidine 
R - - methoxy - - - - - - 
P phenol - - - - - - - - 
K linker - - - - - - - sulfur 
E0 - toluene chloride 
trifluoro 
methyl 
- phenyl - - - 
E1 - - - - - - - - - 
BP-I - - - - 
hydroxy-
aniline 
mercapto-
methyl 
sulfur phenyl 
amino-
pyrimidine 
BP-II - - - - - - - - - 
The A-/hinge zone 
When ATP binds, the adenine moiety is situated in the A-zone. Adenine forms two hydrogen 
bonds to the A-/hinge zone. Among the nine fragments, phenol, pyrazole, pyridine, 
pyrimidine, indole, and amide represent examples of scaffolds that are observed to form 
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hydrogen bonds to that zone. The majority of small-molecule, kinase inhibitors that have been 
developed to date target that zone of the ATP binding site (Liu and Gray, 2006). It has also 
been shown that the hinge-interacting motif may be transferred between differing chemical 
series (Caldwell, et al., 2008). The nine fragment-protein complexes involved incorporated 
eight, differing scaffolds that form hydrogen bonds to the A-/hinge zone (cf. Fig.33). An 
overview thereof is presented in Table 7. 
 
 
Fig.33. A depiction of the overlappings of fragments bound in the A-zone of PKA. The A-zone, or protein-
kinase-hinge zone, binds the adenine moiety when ATP binds. All nine fragments exhibited A-zone interactions. 
 
The BP-I- and K- zones 
The BP-I-pocket (selectivity pocket) is relatively small in the case of PKA due to its being 
“guarded” by the bulky “gatekeeper” residue indicated by the red arrow in Fig.34, which is 
Met-120 in the case of PKA. In the case of fragments 6 and 7, a sulfur-sulfur interaction 
between those fragments and the gatekeeper residue occurs (cf. Appendix 1). The K-zone 
derives its designation from the lysine residue, Lys-72, occurring in PKA. That residue, which 
is indicated by the green arrow in Fig.34, is vital to the catalytic function occurring on the 
kinase, persists throughout much of the protein-kinase family. Fragment 1 interacts with the 
amine in Lys-72 via its carbonyl group. 
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Fig.34. Binding to the BP-I-pocket and K-zone of PKA. The protein is depicted in green and the fragment in 
yellow. The K-zone contains the catalytic lysine, which is indicated by the green arrow, and is Lys-72 in the case 
of PKA. The BP-I-pocket in PKA is largely blocked by the bulky “gatekeeper” residue indicated by the red 
arrow, and is Met-120 in the case of PKA. Fragment 1 picked up an interaction with the amine in Lys-72 via its 
carbonyl group. 
 
Thr-183 represents another amino acid situated in the K-zone, ahead of the DFG-motif 
(184 - 186 in the case of PKA). In the case of the nine fragments involved, Thr-183 exhibited 
three, distinct conformations. Fragments 2, 3, 5, 7, and 9 had conformations where Thr-183 
was arranged in a vertical orientation, similar to the case of the complex formed with ATP 
(pdb-code 1ATP) (Zheng, et al., 1993) (cf. Fig.35 (B)), while in the case of fragments 1, 4, 6, 
and 8, the side chain has a horizontal orientation (cf. Fig.35 (C)).  
 
 
Fig.35. The three conformations of Thr-183 in PKA. (A) depicts the main-chain flip of Thr-183. (B) and (C) 
depict the two conformations of the Asp-184 side chain (DFG-motif).  
 
An interesting conformation of Thr-183 was observed in conjunction with the binding of 
fragment 6. The bulky, methyl-mercapto moiety occurring in that fragment caused a main-
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chain flip that led to a rearrangement of the Thr-183’s carbonyl group such that it pointed 
outward, toward the ATP binding pocket ((A) in Fig.35). That particular main-chain flip is 
rarely observed. The sole published structure of a complex involving native-PKA and an 
inhibitor exhibiting that sort of conformational alteration is that involving staurosporine 
(pdb-code 1STC) (Prade, et al. 1997). The conformation of the carbonyl and trailing 
DFG-motif also led to the kinase acquiring an inactive conformation. The conformation of the 
DFG-motif involved cannot enter into the specific interaction with Mg2+ and ATP that is of 
importance to ATP’s transition to ADP. The main-chain flip involved can also be observed in 
mutant-PKA structures, where Thr-183 is mutated to Ala-183 and observed to form 
complexes with balanol-series inhibitors (Bonn, et al., 2006).  
 
The E0- and R-zones 
An investigation of the fragments involved turned up chemical scaffolds that interacted with 
the E0- and R-zones of the ATP-pocket in PKA. Fig.36 illustrates the interactions occurring in 
those two zones in the cases of fragments 2, 3, 4, and 6. 
 
Fragment 2 Fragment 3 Fragment 4 Fragment 6 
Fig.36. Interactions occurring in the E0- and R-zones, xemplified by the cases o  fragments 2, 3, 4 and 6. 
he E0-zone contains the phenylalanine residue, Phe-327, which is shown in blue in Fig.36, 
 e f
Fragments 2, 3, 4, and 6 exhibited signs that chemical-scaffold interactions had occurred in those zones. 
Scaffolds, such as the toluene in fragment 2, the chloride in fragment 3, the 3-fluoromethyl-group in fragment 4, 
and the phenyl in fragment 6, were observed to pick up interactions in those two zones. Moreover, the phenyl ring 
in fragment 6 nudges the side chain of Glu-127, causing it to point away from the R-zone and ATP binding cleft. 
 
T
specific to the AGC-kinase family. Many protein-kinase inhibitors interact with the E0-zone. 
Among those fragments surveyed under the present study, only four had chemical scaffolds 
situated in that zone. It thus seems that the Phe-327 blocks that zone of the ATP binding site 
in PKA. The R-zone contains the glutamatic-acid residue Glu-127, that shown in red in Fig.36 
in the case of Fragment 6. The importance of that amino acid in PKA-substrate recognition 
88 
  
has been discussed by Gibbs and Craig (1991). The phenyl ring in fragment 6 is observed to 
cause the side chain of Glu-127 to point away from the R-zone and ATP binding cleft. 
 
The P-zone 
The glycine-rich loop in the P-zone spans the nucleotide’s phosphate-binding sites. The loop 
is known to be very flexible, and takes on several conformations in the various protein-kinase 
structures. The overlappings of the nine fragment structures shown in Fig.37 illustrates the 
incidence of various conformations of that loop. Its flexibility is correlated to the high 
B-factors of those residues present in the loop, compared to the average B-factors for the 
protein. Fragment 1 had the most sharply defined glycine-rich loop, where its 4-phenol-group 
undergoes a π-π-interaction with the Phe-54-residue at its tip, resulting in a stiffening of the 
loop conformation and reductions of the B-factors of those residues present in the loop. 
 
Fig.37. Glycine-rich loop conformations. The various conformations of the glycine-rich loop are shown. At the 
tip of the loop, the aromatic residue (Phe-54 in the case of PKA) takes on various conformations in the structures 
of the nine fragments. Binding of fragment 1 (shown in yellow) stabilizes the loop conformation via interactions 
occurring between its 4-phenol moiety and the Phe-54 residue. 
 
The structures presented in the results section of this dissertation are illustrative of the variety 
of molecular scaffolds that interact with the ATP binding pocket. The structures obtained 
from X-ray-diffraction analyses reveal the manners in which all fragments involved bind to 
PKA’s hinge zone, in addition to demonstrating that they pick up interactions in several other 
zones of the ATP binding pocket. Those structures disclose the relatively high flexibilities of 
certain zones, such as the glycine-rich loop or the residues surrounding the DFG-motif. 
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Chapter 4 
DISCUSSION 
 
 
The results obtained exemplify the two FBLD-approaches involved. Both employed PKA as 
the target protein in studies aimed at characterizing and analyzing protein-fragment interac-
tions. The first approach investigated the fragment-PKA interactions occurring, which were 
studied utilizing three different techniques, (I) surface-plasmon-resonance (SPR) analyses, (II) 
high-compound-concentration biochemical assays (HCA), and (III) protein crystallography. 
Under the second approach, biochemical-assay data was utilized for selecting fragments for 
structure determinations by means of protein crystallography. The methods employed and the 
results obtained are summarized in Table 8. 
 
Table 8. The methods employed in, and the results obtained from, the two FBLD-approaches involved. 
The table below summarizes the results obtained from both FBLD-approaches employed in conjunction with this 
dissertation. Under Approach 1, a combination of SPR, HCA, and protein crystallography was applied to a 
library of fragments that were screened, characterized, and had the 3-D-structures of the complexes that they 
formed analyzed. Approach 2 focused on biochemical assays and protein crystallography in order to determine 
the 3D-structures of the complexes that formed when fragments bonded to PKA. 
 
 
1. Screening 
(via SPR and HCA) 
2. Characterization
(via SPR and HCA)
3. 3D-structure 
determinations 
(via X-ray diffraction)
4. No. of 3D-structures 
obtained/(not obtained)
Approach 1 257 68 26 9 (17) 
Approach 2 
67 
(from biochemical 
assays only) 
- 25 21 (4) 
 
SCREENINGS UTILIZING SPR AND HCA 
Under the first approach, a library of 257 fragments was screened for binding to PKA utilizing 
SPR and HCA, and 68 of the fragments involved were classified as hits. SPR was utilized for 
investigating binding of fragments to PKA under direct-binding assays, where fragments were 
injected across a sensor surface coated with immobilized PKA, while HCA was utilized for 
determining the extents to which fragments inhibited PKA-substrate phosphorylation. The 
results of screenings based on those two methods were only weakly correlated. Only eighteen 
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of the 60 SPR-hits and 26 HCA-hits showed up as hits under both screenings. Since the exper-
imental techniques involved differ in several ways, including the mechanisms employed for 
detecting fragment binding, direct comparisons of the results obtained from them are difficult.  
 
Under SPR, the target protein is immobilized on the substrate matrix and binding of fragments 
to the target protein is measured in a stream of fragments, while under HCA, target-protein 
activities are quantified in terms of the concentrations of solvated, phosphorylated substrate 
that result. Since the direct-binding assays employed under the SPR-approach are incapable of 
measuring the changes in target-protein biological activity that occur upon fragment binding, 
screening for agonists would be impossible if only SPR were employed. The extents to which 
fragments that were classified as hits under SPR alone bind to PKA without exhibiting any 
inhibition under HCA were not studied in conjunction with this dissertation, but would be an 
interesting subject for further investigations. 
 
Another difference between the two techniques is the fragment concentrations employed 
during screenings, which are 200 µM in the case of SPR and 100 µM in the case of HCA. 
High fragment concentrations had to be chosen in order to facilitate detection of low-affinity 
interactions. Furthermore, the fragment concentrations chosen represented a compromise 
between affinity range and assay stability in relation to nonspecific fragment interactions, 
such as binding of fragment precipitates, micelles, or aggregates to various components 
involved in the assays. At high fragment concentrations, fragment-composition equilibrium 
points are shifted toward multimeric states and formation of fragment aggregates, which could 
increase the numbers of both site-specific and nonspecific interactions involved. In fact, 
increased numbers of nonspecific interactions correlated to high fragment concentrations have 
already been reported in the case of SPR-investigations (Hämäläinen, et al., 2008). The 
interaction mechanisms acting between the fragments and target proteins involved are 
schematically depicted in Fig.38.  
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Fig.38. A schematized depiction of fragment-fragment and fragment-protein interactions. (A) Interactions 
between fragments and the target protein. Solvated fragments should ideally be present in the form of monomers, 
since they are capable of interacting with the target binding site, although they are also capable of either 
interacting with multiple binding sites or undergoing nonspecific interactions with the target. (B) Interactions of 
fragment multimers with the target protein. An equilibrium among solvated fragment monomers, oligomers, and 
formation of fragment micelles will set in (McGovern, et al., 2003). (C) At higher fragment concentrations, large 
fragment aggregates may be present. (1) Site-specific binding. Fragment monomers bind to a single binding site. 
(2) Bisite, or multiple-site, binding, under which fragment monomers bind to several protein binding sites. (3) 
Nonspecific binding. Fragment oligomers, micelles, or aggregates bind to the protein in a nonspecific manner 
(McGovern, et al., 2002; Gianetti, et al., 2008).  
 
The monomeric forms of fragments are capable of interacting with the protein-binding site 
(cf. Fig.38 (1) and (A)). However, they are also capable of undergoing interactions with 
alternative binding sites (Fig.38 (2) and (A)). Since no competitive experiments were 
conducted in conjunction with the SPR-approach employed here, no further characterizations 
of fragments classified as belonging to Group II (cf. p. 71) were possible. Although fragments 
from that group exhibited typical transient binding, their binding responses exceeded those 
expected for 1:1, fragment-protein interactions. A certain proportion of weakly soluble 
fragments will aggregate in solution. Small-molecule aggregates tend to exhibit nonspecific 
binding to target proteins (cf. Fig.38 (C) and (3)). The two types of assays involved here, SPR 
and HCA, yielded differing responses to nonspecific binding phenomena, which might be one 
reason for the differences in the results obtained under them, in accordance with those results 
reported by Gianetti, et al. (2008), where it was shown that given fragments may exhibit 
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differing behaviors, depending upon the parameters, such as the presence and type of 
detergents, buffer composition, pH, presence/absence of cofactors, etc., employed in 
screening assays. For example, pH-variations might cause changes in the protonation states of 
the compounds or amino acids present in protein-binding pockets, while detergents might 
affect compound solubilities. Under HCA, fragment aggregates might interfere with assay 
readouts due to, e.g., fluorescence quenching or fluorescence, exhibit “nonspecific” binding to 
the enzymes involved during stages aimed at boosting signal levels, or even cause disruption 
of the proteins employed in assays (McGovern, et al., 2003). Readouts from screenings that 
employed the SPR-setup are less sensitive to interference emanating from assays, since they 
are a measure of direct binding of fragments to the target protein, which means that 
employing the SPR-setup should allow avoiding the enzymatic, signal-enhancement stages 
occurring under HCA and reduce the number of prospective sources of interference.  
 
Overall, the outcomes of the screenings conducted yielded a relatively large number of 
fragments that were classified as hits. The high fragment concentrations employed in the 
screenings surely increased hit rates, since even very low binding affinities are detectable at 
high fragment concentrations (Hämäläinen, et al., 2008). Furthermore, employment of a 
protein-kinase-targeted library probably further increased hit rates. Several chemical scaffolds 
were identified among the hits resulting from the SPR/HCA-screenings conducted.  
 
HIT CHARACTERIZATION 
Hit characterization was undertaken in order to allow more-stringent examinations of the 
natures of the interactions of the fragments involved with PKA and determinations of their 
affinity constants, KD, under SPR, and IC50, under HCA. 
 
Seven binding constants fell within the same range under both assays. One exception is 
fragment 178, for which a KD of 750 µM and an IC50 of 38 µM was determined. Eight 
fragments involved in SPR-hit characterization exhibited responses having characteristics that 
were indicative of concentration-dependent effects occurring within the concentration range 
involved, particularly at the higher concentrations. Such fragments have been classified as 
Group IV (cf. p. 71). Fig. 24 (cf. p. 77) depicts the concentration-dependent behavior of 
fragment 19 during SPR-titration. Similar compounds have been investigated via SPR by 
Gianetti, et al. (2008) and their results suggest that the fragments involved are poor candidates 
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for protein-crystallographic studies (Gianetti, et al., 2008), in view of the concentration-
dependent aggregates that might occur. However, as stated in the caption to Fig.38, 
equilibrium between fragments present in the form of oligomers, micelles, or aggregates, and 
fragments present in the form of solvated monomers will set in. Fragment 20 represents an 
example of a fragment forming a complex whose crystalline structure could be determined, 
even though it was classified as being subject to concentration-dependent effects. Further-
more, the number of affinity constants determined under subsequent titrations was reduced 
from 60 screening hits under SPR and 26 screening hits under HCA to 24 screening hits under 
SPR and 12 screening hits under HCA, where eight of the latter were classified as hits under 
both SPR-screenings and HCA-screenings. Under the fragment-library set up, many 
fragments reached their solubility limits at the higher concentrations. Careful design of the 
fragment library involved and devoting special attention to fragment solubilities is therefore 
critical. The fragments involved should ideally have empirically determined solubilities 
covering ranges extending beyond the highest fragment concentrations employed in titrations. 
 
Subsequent structure determinations employing protein crystallography revealed their binding 
modes to PKA’s hinge zone. The KD or IC50 of every fragment, for which the structure of the 
complex it formed with PKA could be determined, was computed. On the other hand, no frag-
ment-PKA-complex structures could be determined for those fragments, for which neither 
SPR- nor HCA-titrations yielded usable results. It should be obvious that conducting 
measurements at a single concentration, utilizing either SPR or HCA, yields weak selection 
criteria for use in subsequent crystallographic studies under FBLD. Further titrations will be 
essential, since they significantly increase the probabilities of obtaining the structures of 
fragment-target-protein complexes via protein crystallography*. 
 
The outcomes of the experiments conducted in conjunction with this dissertation demon-
strated that the SPR-approach is sensitive enough to allow detecting fragment-screening res-
ponses, which is in agreement with conclusions reached under earlier SPR-based fragment 
studies (Nordström, et al., 2008; Hämäläinen, et al., 2008). 
 
___________________________________________________________________________ 
* The success rate for determinations of the structures of fragment-PKA complexes increased from 13 % 
following primary screenings to 30 % following subsequent titrations. 
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PROTEIN-FRAGMENT COMPLEX FORMATION AND STRUCTURE 
DETERMINATIONS EMPLOYING PROTEIN CRYSTALLOGRAPHY 
Protein crystallography is the method of choice for obtaining detailed data on 3D-fragment-
protein interactions. The crystalline structures of fragment-target-protein complexes reveal 
fragments’ chemical environments.  
 
Under the first approach, which involved protein-crystallography analyses, nine of 
26 fragments yielded the structures of the complexes involved, while under the second 
approach, 21 of 25 fragments yielded the structures of the complexes involved. A comparison 
of the crystallographic results obtained under the two approaches suggests that differences in 
the designs of the experiments involved are the primary reason for variations in their success 
rates (cf. Table 8). The much higher success rate under the second approach may be partly 
explained by the differing concentration ranges employed in the screening and titration runs 
conducted under the first approach and the conditions under which HTS/biochemical assays 
were conducted in the case of the second approach. Under the first approach, all fragments 
had estimated affinities falling in the mid-µM to low-mM range, while, under the second 
approach, all had estimated affinities falling in the low-µM range or higher, which eliminated 
many concentration-related issues under the second approach and reduced the number of 
“false positives.” 
 
High occupancies of binding sites are necessary if electron densities are to be reliably 
detected, which means that certain ligand concentrations in the protein solutions involved 
must be reached. A rule of thumb is that protein concentrations exceeding KD by at least a 
factor of 5 to 10 will be necessary if reasonably well-defined ligand electron densities at 
binding sites are to be obtained. The ratios of fragments’ affinities to their maximum-
utilizable concentrations are thus the factors influencing empirical results. The affinity/solu-
bility ratios of weakly soluble fragments affect both the probability that the structures of 
fragment-protein complexes will be determinable and the probability that fragment binding 
constants will be derivable from assays. In the case of the investigations conducted here, 
computed solubilities, clogS(7.4), were employed as selection parameters in order to increase 
the likelihood that the structures of fragment-protein complexes would be determined. Never-
theless, computed solubilities are frequently inaccurate and can lead to over/underestimations 
of solubilities relative to empirically determined solubilities. Empirical assays, such as those 
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employing optical-dispersion techniques, filtering-assay techniques, or NMR-detection of 
compound aggregates, may be employed in order to arrive at better estimates of ligands’ 
solubilities in given solutions. Appendix 1 lists examples of empirically determined and 
computed solubilities (clogs(7.4)), where the data involved was extracted from MerckSer-
ono’s in-house database. However, under the second approach, all hit-fragments had 
IC50-values falling in the low-µM range and solubility overestimations due to the computa-
tional methods employed were much less critical than under the first approach.  
 
In the case of the experimentation conducted in conjunction with this dissertation, higher 
DMSO-concentrations and detergents were employed in order to increase to affinity/solubility 
ratios, which, however, increased the stresses exerted on protein crystals and adversely 
affected the qualities of the diffraction patterns of many of the protein crystals involved. The 
protein crystals involved were therefore stabilized by crosslinking employing glutaraldahyde, 
which allowed employing higher fragment concentrations, higher DMSO-concentrations, and 
longer soaking periods, and facilitated detection of another three fragment-protein complexes. 
However, crosslinking protein crystals might impose limitations on protein flexibility, thereby 
preventing the changes in protein conformation essential to formation of some types of 
fragment-protein complexes. Nevertheless, in the case of several structures, large conforma-
tional changes in flexible loops and shifts from alpha helices to other structure conformations 
were observed, even following crosslinking. In our experience, controlled crosslinking can 
stabilize protein crystals, while simultaneously permitting conformational changes in the 
protein contained therein, i.e., can facilitate the formation of fragment-protein complexes.  
 
One major difference in the experimental setups employed in the crystallographic analyses 
and the SPR/HCA-screenings involving PKA was the presence of 19 amino-acid polypep-
tide PKI, which was employed as a cocrystallizing agent. Both attempts to conduct 
SPR/HCA-screenings involving PKA in the presence of PKI, as well as crystallization 
conditions yielding strongly diffracting crystals, without need for employing PKI, failed. 
Estimates of the effect of PKI on fragment binding to PKA were thus unobtainable. PKI might 
have caused reductions of the binding affinities of some fragments, thereby hindering 
determinations of their crystalline structures.  
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EMPLOYMENT OF FRAGMENT COMPLEXES 
The aim of FBLD is designing lead molecules, based on initial hit-fragments. Data on 
fragment 3D-binding modes may be employed in various ways in conjunction with that effort. 
It might be argued that, in the case of the second approach, under which available biochemi-
cal-assay data were utilized in selecting hit-fragments, discoveries of new chemical scaffolds 
will be few and far between. However, fragments are smaller than typical HTS-hits or lead 
molecules, and therefore subject to fewer structure constraints on their interactions with target 
proteins. “Old” chemical scaffolds thus can interact with protein binding sites in novel and 
unexpected ways, thereby promoting arrival at new approaches to designing lead molecules. 
The investigations conducted in conjunction with this study revealed new interactions 
occurring in the ATP binding pocket in PKA and identified several novel chemical scaffolds. 
 
Fragment growing, fragment linking, and fragment merging represent techniques commonly 
employed in FBLD for optimizing fragments in order to obtain more-lead-like molecules 
having greater affinities. Any fragment-PKA complex identified under this study may be 
employed as the starting point for those fragment-optimization techniques. Overlappings of 
fragment structures and known PKA-inhibitors obtained from PDB (cf. Fig.39) suggests that 
chemical scaffolds might be interchanged between molecules, namely, between two 
fragments, between two, large inhibitors, and between the fragments involved and the larger 
inhibitors, and combined in all conceivable manners. Knowledge of fragments’ 3D-binding 
modes generates new ideas, ideas that may be applied to the design of new, candidate, drug 
compounds. 
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(A) (B) (C)
(E) (F) (D) 
Fig.39. Fragment binding modes overlapped by known PKA-inhibitor molecules. (A) Fragment 5 (shown in 
brown) and 2UVY-inhibitor, (B) Fragment 5 (shown in brown) and 2UVX-inhibitor, (C) Fragment 3 (shown in 
dark blue) and 1BX6-inhibitor, (D) Fragment 7 (shown in yellow) and 2GNF-inhibitor, (E) Fragment 1 (shown 
in brown) and 1RE8-inhibitor, (F) Fragment 3 (shown in dark blue) and 2UW3-inhibitor. These overlappings of 
fragment structures by the structures of known PKA-inhibitors obtained from PDB suggest that chemical 
scaffolds might be interchanged between molecules, between two fragments, between two large inhibitors, and 
between the fragments involved and the larger inhibitors, and combined in all conceivable manners.  
OTHER METHODS EMPLOYED IN FBLD 
Protein crystallography is the method most frequently employed for determining the struc-
tures of fragment-target-protein complexes. Nevertheless, it is a relatively low-throughput 
method and unsuitable for screening large numbers of ligands, even if strongly diffracting 
crystals of the target protein are available. An alternative approach is employing in-silico-
docking methods for categorizing fragment binding modes (Oblak, et al., 2005; Pickett, et al., 
2003). The computational methods involved allow considering multiple sets of compound 
parameters and assay interaction data in assessments of fragment characteristics. However, 
since fragments contain fewer functional groups that computational software can employ in 
categorizing fragments’ interactions with target proteins, theoretically predicting fragment 
binding modes and fragment-protein interactions is difficult. A combination of empirical and 
computational methods might therefore be the better choice of tool for fragment elaboration in 
conjunction with FBLD. 
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4.1 CONCLUSIONS 
This work presents the results obtained from two fragment-screening approaches involving 
cAMP-dependent protein-kinase A (PKA). Under the first approach, fragment-protein 
interactions were studied employing surface plasmon resonance (SPR), high-concentration 
biochemical assays (HCA), and protein crystallography, while the second approach employed 
available biochemical-assay data in the form of HTS-screening data or other activity-assay 
data for selecting fragment-like molecules to be subjected to crystallographic analyses. The 
results obtained were in the form of empirically determined binding constants and the 
3-dimensional structures of fragment-PKA complexes. The chemical environment of the ATP 
binding site in PKA was mapped, employing fragment interactions suitable for use as new 
starting points for lead generation. 
 
Under the first approach, i.e., that employing protein crystallographic analyses, nine of the 
26 fragments that had been selected yielded fragment-protein complexes, which demonstrated 
that ample numbers of fragment-PKA interactions were occurring and that binding 
characteristics that could be useful in upgrading fragments into lead-like molecules were 
involved. Although those nine PKA-fragment structures were inadequate to serve as a solid 
base for statistical analyses, in general, the results obtained indicate that the two screening 
methods involved, SPR and HCA, yield outcomes that are in a good agreement with one 
another. The residual differences involved may be largely attributed to two factors, the 
presumed formation of fragment aggregates and their nonspecific binding to PKA and/or the 
narrow width (< 200 µM) of the screening window employed in the case of HCA. 
 
Direct comparisons of the results obtained from the two screening methods are difficult, 
particularly if the differences in the experimental setups involved are taken into account. SPR 
may be set up in the form of a label-free assay well suited to the primary screening of 
fragment libraries and capable of detecting hit-fragments having millimolar affinities. The 
advantage of employing SPR as a screening method is that it consumes relatively small 
quantities of proteins and provides responsivities and throughput rates sufficient to allow 
screening libraries consisting of hundreds to thousands of fragments for binding to target 
proteins within days. Furthermore, analyses of SPR titration data allow rapidly identifying 
nonstoichiometric binders and prospective aggregates. On the other hand, although the 
concentration ranges involved in most HCA-screenings remained below millimolar levels, 
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HCA might well be employed a high-throughput mode, and therefore might be a means for 
readily screening tens of thousands to hundreds of thousands of fragments per day. 
 
Under the second approach, 21 of the 25 fragments involved yielded the structures of their 
protein complexes. That high success rate may be attributed to the conservative selection 
criteria (> 50 % inhibition at 10 µM fragment concentration) employed in identifying hit-
fragments. If similar selection criteria had been applied to the results of typical HTS-runs, 
much higher hit ratios would be expected, which would have led to many novel chemical 
scaffolds being identified as new, prospective, starting points for lead-discovery investiga-
tions.  
 
The two approaches involved thus provided interaction data and crystalline structures that can 
serve as bases for developing PKA-inhibitors. The methods employed here are generally 
applicable to the study of other enzymes and therefore useful in FBLD. 
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APPENDIX 1 
Table 9. Binding modes for the nine fragments involved. The table below covers all nine fragments, and 
presents supplementary data on their molecular weights, biochemical-inhibition factors, and computed and 
measured solubilities. Also included are diagrams depicting their binding modes and brief descriptions of the 
fragment-protein interactions involved. 
 
Fragment 1 
N
O
O
N
O
 
MWT: 270.29 
Inhibition: 41 % at 10 µM fragment concentration 
Solubility (computed pH: 7.4): 12.9 mM 
Solubility (kinetic): > 200 µM 
 
 
Fragment 1 binds to the kinase’s A-/hinge zone, with its 4-phenol group acting 
as a donor/acceptor. Its pair of nitrogen atoms interacts with the DFG-motif in 
the K-zone and the glycine-rich loop in the kinase’s P-zone. The carboxylic acid 
interacts directly with the (K-zone) Lys-72. Closer to the solvent, the fragment’s 
4-phenol group interacts with the tip of the (P-zone) glycine-rich loop, where 
the Phe-54-residue undergoes a π-π-interaction with the 4-phenol group. 
  
Fragment 2 
O
N
N
N
 
MWT: 239.28 
Inhibition: 9 % at 10 µM fragment concentration 
Solubility (computed pH: 7.4): 0.362 mM 
Solubility (kinetic): > 200 µM 
 
 
Fragment 2 forms three hydrogen bonds with the kinase’s A-/hinge zone, one 
via its amine group, which interacts with the main-chain carboxyl-group of 
Val-123, and two to the Glu-121 hinge residue, via the indazole. Its toluene 
group is directed toward the (E0-zone) aromatic residue, Phe-327, specific to 
AGC-kinases. 
  
Fragment 3 
N
N Cl
O
 
MWT: 208.65 
Inhibition: 44 % at 10 µM fragment concentration 
Solubility (computed pH: 7.4): 1.26 mM 
Solubility (kinetic): 100 µM 
 
 
Fragment 3 forms two hydrogen bonds with the kinase’s A-/hinge zone, where 
the two nitrogen atoms on its pyrazole group act as donor and acceptor, 
respectively, and interact with the Glu-121 and Val-123. The 3-chloro radical on 
its methoxy-phenyl group is situated near the kinase’s (E0-zone) Phe-327, at 
precisely the same location as the trifluoro group on fragment 4 and the toluene 
ring on fragment 2. 
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Fragment 4  
N
O
N
N
F
FF
 
MWT: 231.18 
Inhibition: 13 % at 10 µM fragment concentration 
Solubility (computed pH: 7.4): 10 mM 
Solubility (kinetic): > 200 µM 
 
 
Fragment 4’s indazole-amine group forms three hydrogen bonds with the 
kinase’s A-/hinge zone. Its trifluoro group is situated within interaction range of 
the kinase’s (E0-zone) Phe-327, whose π-electrons interact with its electronega-
tive fluorine atoms. Superimposing the diagram for fragment 4 on that for 
fragment 3 reveals that the triflouro group on fragment 4 coincides with the 
chlorine atom on fragment 3, and therefore interacts with the protein in a similar 
manner.  
  
Fragment 5 
N
N
NN
N
N
O
 
MWT: 242.24 
Inhibition: 20 % at 10 µM fragment concentration 
Solubility (computed pH: 7.4): 4.13 M 
Solubility (kinetic): > 200 µM 
 
Fragment 5’s pyrazole-pyrimidine group forms two hydrogen bonds with the 
kinase’s A-/hinge zone. Its hydroxyl-aniline group is directed toward the 
kinase’s gatekeeper and BP-I/specificity pockets. An interaction between its 
aniline group’s π-electron cloud and the electrons of the sulfur atom in the 
gatekeeper residue, Met-120, was observed. 
  
Fragment 6   
N
N
N
S
N
O
 
MWT: 248.31 
Inhibition: 33 % at 10 µM fragment concentration 
Solubility (computed pH: 7.4): 24.3 mM 
Solubility (kinetic): > 200 µM 
 
 
Fragment 6 has an amide group that acts as a hinge-binder in the kinase’s A-
zone. Its phenyl group is situated in the pocket close to the (E0-zone) Phe-327, 
and its mercapto-methyl group is directed toward the (BP-I-pocket) gatekeeper 
residue, Met-120. Interestingly, the main chain flips 180° at the location of the 
(K-zone) Thr-183, which is probably due to the bulkiness of the sulfur atom on 
the ligand present in that zone. Also noteworthy is that the gatekeeper residue 
(Met-120) is thrust “upward” into the BP-I pocket, compared to the case for the 
other PKA-structures presented here and published in the pdb-database. 
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Fragment 7 
N
N
O
N
S
 
MWT: 231.28 
Inhibition: 43 % at 10 µM 
Solubility (computed pH: 7.4): 83.4 mM 
Solubility (kinetic): 50 µM 
 
 
Fragment 7 binds via a hydrogen bond that binds its pyridine group to the 
kinase’s A-/hinge zone. Its thiocarbamyl group interacts with the aspartic-acid 
residue situated in the (Asp-184/K-zone) DFG-motif. Its sulfur group is directed 
toward the specificity/BP-I-pocket gatekeeper residue, Met-120. The nitrogen 
atom on its pyridine ring interacts with the Glu-327 present in the kinase’s 
P-zone. The glycine-rich loop is not clearly differentiated from the protein’s 
structure, which might be due to its relatively large, compared to the average for 
the protein, B-factors and diffuse electron density. 
  
Fragment 8 
Cl
N
O
N
 
MWT: 270.72 
Inhibition: 33 % at 10 µM fragment concentration 
Solubility (computed pH: 7.4): 708 µM 
Solubility (kinetic): 25 µM 
 
 
Fragment 8 binds to PKA, where its chlorine atom interacts with the kinase’s 
A-/hinge zone. Its phenyl group is situated in the same pocket as that on 
fragment 1, i.e., that close to the (E0-zone) Phe-327 residue. Its indole-carbonyl 
group points outward, toward the solvent/P-zone. 
  
Fragment 9   
N
S N
N
N
N
N  
MWT: 218.24 
Inhibition: 22 % at 10 µM fragment concentration 
Solubility (computed pH: 7.4): 379 µM 
Solubility (kinetic): > 200 µM 
 
 
The amino-pyrimidine groups on fragment 9 bind to the kinase’s A-/hinge zone. 
One has its sulfur atom pointing toward the gatekeeper residue (the Met-120 
situated between the kinase’s A-zone and BP-I pocket), and the other points 
toward the solvent (P-zone) and picks up interactions with surrounding residues 
via interactions with water molecules. 
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APPENDIX 2 
Table 10. The results of the X-ray-crystallographic investigations conducted. The table below covers all nine 
fragments detected in the electron density of the ATP binding pocket in PKA, and includes their molecular 
structures, binding affinities, and inhibition constants, brief descriptions of the interactions occurring between the 
respective fragments and protein, and diagrams illustrating the 3D-binding modes involved. 
 
Fragment 178 
S
N
N
N2H
 
MWT: 205.28 
HCA IC50: 38 µM 
SPR KD: 500 µM – 1 mM 
 
Fragment-protein interactions: Fragment 178 binds to PKA via two hinge 
interactions. Its 6-nitrogen acts as an acceptor, and its amide nitrogen acts as a 
donor with respect to the main-chain amide and carboxyl group on the hinge 
residue, Val-123. Its electron-rich sulfur atom is readily apparent in the electron 
density and points upward, toward the Met-120 residue, yielding a sulfur-sulfur 
interaction. Its saturated pyrimidine ring is not readily evident in the electron-
density distribution. 
  
Fragment 6 
N
NH
N
NH
N
 
MWT: 225.6 
HCA IC50: - 
SPR KD: 100 µM – 200 µM 
 
Fragment-protein interactions: Fragment 6 binds to the protein, where its purine 
moiety forms two hydrogen bonds to the hinge zone at the ATP binding site. The 
benzene group is rotated 90° relative to the purine scaffold and is situated in the 
ribose-binding pocket. 
  
Fragment 20 
N
N
HN
N
S
 
MWT: 166.21 
HCA IC50: 51 µM 
SPR KD: Binding occurred at low concentrations and concentration-dependent 
aggregation was observed at the higher fragment concentrations (> 70 µM); its 
affinity (KD) was not computed. 
 
Fragment-protein interactions: Fragment 20 bonds to the protein, where its 
purine moiety forms two hydrogen bonds to the hinge zone at the kinase-ATP-
binding site. The 5-sulfur atom is clearly visible in the electron-density distribution 
and directed toward the ribose pocket. 
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Fragment 23 
N
N
H
OH
NH2
S
 
MWT: 223.30 
HCA IC50: - 
SPR KD: 500 µM – 1 mM 
 
Fragment-protein interactions: Fragment 23 binds to the protein, where its 
phenol moiety acts as both a donor and an acceptor with respect to the hinge zone 
in the ATP-pocket. Its ethyl radical points downward, toward the ribose pocket, 
and its sulfonamide group points upward, toward the DFG-residue, Asp-184, and 
the gatekeeper residue, Met-120.  
  
Fragment 103 
N
N
N
N NH
N
 
MWT: 218.26 
HCA IC50: 100 µM 
SPR KD: 70 µM 
 
Fragment-protein interactions: Fragment 103 binds to the protein, where its 
purine moiety forms two hydrogen bonds to the hinge zone at the kinase-ATP-
binding site. Its methyl-piperidine group takes on a chair conformation and is 
situated in the ribose pocket. 
  
Fragment 154 
N
N NH
N
NH F
 
MWT: 229.22 
HCA IC50: 27 µM 
SPR KD: a weak binder (KD > 1 mM) 
 
Fragment-protein interactions: Fragment 154 binds to the protein, where its 
pyrazole-pyrimidine moiety forms two hydrogen bonds to the latter’s hinge zone. 
Its flourophenyl group points downward, toward the ribose pocket, and interacts 
with the Phe-327-residue’s π-electrons. That residue is specific to just a few 
members of the AGC-protein-kinase family and blocks part of the ATP binding 
pocket, where many small-molecule, protein-kinase inhibitors are frequently 
observed to interact. 
  
Fragment 162 
N
N
HN
N
NH
 
MWT: 243.31 
HCA IC50: 86 µM 
SPR KD: 100 µM 
Fragment-protein interactions: The purine in fragment 162 forms two hydrogen 
bonds to the ATP-pocket’s hinge zone. An interaction with the Thr-183-residue is 
picked up from the nitrogen in its purine ring, via a water molecule. Its cyclo-
hexane ring points away from the hinge, toward the solvent zone.  
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Fragment 192 
NH2
NN
NH
F
N
 
MWT: 205.20 
HCA IC50: - 
SPR KD: 400 µM 
 
Fragment-protein interactions: Interestingly, fragment 192 exhibited two, 
distinct binding modes, both of which were readily apparent in the electron-density 
distribution obtained following collection of protein-crystallographic data. Both 
conformations have the aminoamide as their hinge-binding structure. However, in 
one of those conformations, the flourophenyl group points toward the DFG-motif, 
and, in the other, it points toward the ribose pocket. 
  
Fragment 236 
N
S
O
O
N2H  
MWT: 248.30 
HCA IC50: 59 µM 
SPR KD: 70 µM 
 
Fragment-protein interactions: Fragment 236 binds to the protein, where its 
benzofuran group interacts with the kinase’s hinge zone. Its thiophene ring is 
directed toward the solvent and its amine group picks up an interaction with the 
Glu-127-residue situated in the ribose-binding pocket. 
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APPENDIX 3 
Table 11. Characterization data for all those fragments contained in the library. The first column lists the 
fragment number, the second column contains a +/– indicating whether the fragment involved was classified as a 
hit/no hit, respectively, under the SPR-screenings conducted, the third column lists the values of KD determined 
from those SPR-screenings, the fourth column lists the fragment binding affinities determined in conjunction 
with SPR-hit characterization, the fifth column contains a +/– indicating whether the fragment involved was 
classified as a hit/no hit, respectively, under the HCA-screenings conducted, and the sixth column 6 the values of 
IC50 determined in conjunction with HCA-hit characterization. The seventh column contains a +/– indicating 
whether an X-ray-diffraction structure determination was conducted for the fragment involved. The column 
listing binding affinities states the respective ranges involved, where “cd” indicates that concentration-dependent 
aggregation occurred, “ns” indicates that nonstoichiometric binding occurred, “ss” indicates that 
superstoichiometric binding occurred, and “i” indicates that irreversible/pseudo-irreversible interactions were 
involved. Characterization as a “weak binder” indicates that although the fragment involved exhibited typical 
transient binding, its binding affinity was not computed. Fragments characterized as “general promiscuous” or 
“nonbinder” have also been included.  
 
FRAGMENT 
NO. 
SPR-SCREENING SPR-KD 
[µM] 
BINDING AFFINITY HCA-SCREENING HCA-IC50
[µM] 
X-RAY
1 —     —   — 
2 —     —   — 
3 —     —   — 
4 —     —   — 
5 —     —   — 
6 + 150 100 µM – 200 µM —   + 
7 —     —   — 
8 —     —   — 
9 —     —   — 
10 —     —   — 
11 —     —   — 
12 —     —   — 
13 —     —   — 
14 —     —   — 
15 —     —   — 
16 —     —   — 
17 —     —   — 
18 —     —   — 
19 —   cd, weak binder +   — 
20 —   cd/i, binder + 51 + 
21 +   Weak binder —   — 
22 +   Weak binder —   — 
23 + 750 500 µM – 1 mM —   + 
24 —   cd, binder +   — 
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25 +   weak binder —   — 
26 —     —   — 
27 —     —   — 
28 —     —   — 
29 —     —   — 
30 —     —   — 
31 +   weak binder —   — 
32 —     —   — 
33 —     —   — 
34 —     —   — 
35 —     —   — 
36 —     —   — 
37 —     —   — 
38 —     —   — 
39 —     —   — 
40 —     —   — 
41 —     —   — 
42 —     —   — 
43 —     —   — 
44 —     —   — 
45 —     —   — 
46 —     —   — 
47 —     —   — 
48 —     —   — 
49 +   general promiscuous —   — 
50 —     —   — 
51 —     —   — 
52 —     —   — 
53 —     —   — 
54 —     —   — 
55 —     —   — 
56 —     —   — 
57 + 35 20 µM – 50 µM + 110 — 
58 +   nonbinder —   — 
59 + 300 200 µM – 400 µM —   — 
60 +   weak binder —   — 
61 —     —   — 
62 —     —   — 
63 —     —   — 
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64 —     —   — 
65 + 65 60 µM – 70 µM + 73 — 
66 +   weak binder —   — 
67 —     —   — 
68 —     —   — 
69 —     —   — 
70 —     —   — 
71 —     —   — 
72 —     —   — 
73 +   nonbinder —   — 
74 +   ns/i —   — 
75 —     —   — 
76 —     —   — 
77 —     —   — 
78 —     —   — 
79 +   ns/i + 38 — 
80 +   cd, weak binder +   — 
81 —     —   — 
82 —     —   — 
83 +   weak binder —   — 
84 —     —   — 
85 —     —   — 
86 —     —   — 
87 +   ns +   — 
88 +   weak binder —   — 
89 + 100 100 µM +   — 
90 —     —   — 
91 —     —   — 
92 —     —   — 
93 —     —   — 
94 —     —   — 
95 —     —   — 
96 + 15 15 µM +   — 
97 —     —   — 
98 +   nonbinder —   — 
99 +     —   — 
100 —   ss/i +   — 
101 —     —   — 
102 —     —   — 
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103 — 70 70 µM + 100 + 
104 —     —   — 
105 —     —   — 
106 —     —   — 
107 —     —   — 
108 —     —   — 
109 —     —   — 
110 +   weak binder —   — 
111 —     —   — 
112 —     —   — 
113 —     —   — 
114 +   weak binder —   — 
115 —     —   — 
116 —     —   — 
117 —     —   — 
118 —     —   — 
119 +   cd, weak binder —   — 
120 —     —   — 
121 —     —   — 
122 + 750 0.5 mM – 1 mM +   — 
123 + 700 700 µM +   — 
124 —     —   — 
125 —   ns +   — 
126 —     —   — 
127 —     —   — 
128 —     —   — 
129 —     —   — 
130 +   nonbinder —   — 
131 —     —   — 
132 —     —   — 
133 —     —   — 
134 —     —   — 
135 —     —   — 
136 —     —   — 
137 —     —   — 
138 —     —   — 
139 + 150 100 µM – 200 µM + 64 — 
140 + 100 100 µM + 23 — 
141 —     —   — 
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142 —     —   — 
143 —     —   — 
144 —     —   — 
145 —     —   — 
146 —     —   — 
147 —     —   — 
148 —     —   — 
149 +   ss/I, cd/I, weak binder —   — 
150 +   nonbinder —   — 
151 —     —   — 
152 —     —   — 
153 —     —   — 
154 +   weak binder + 27 + 
155 —     —   — 
156 —     —   — 
157 —     —   — 
158 —     —   — 
159 —     —   — 
160 —     —   — 
161 —     —   — 
162 + 100 100 µM + 86 + 
163 —     —   — 
164 —     —   — 
165 —     —   — 
166 —     —   — 
167 —     —   — 
168 +   weak binder —   — 
169 —     —   — 
170 —     —   — 
171 —     —   — 
172 —     —   — 
173 —   nonbinder +   — 
174 —     —   — 
175 —     —   — 
176 —   ns/i +   — 
177 +   weak binder —   — 
178 + 750 500 µM + 38 + 
179 —     —   — 
180 —     —   — 
123 
  
181 —     —   — 
182 +   weak binder —   — 
183 —     —   — 
184 —     —   — 
185 —     —   — 
186 —     —   — 
187 —     —   — 
188 —     —   — 
189 —     —   — 
190 —     —   — 
191 —     —   — 
192 + 400 400 µM +   + 
193 + 80 80 µM —   — 
194 —     —   — 
195 +   weak binder —   — 
196 —     —   — 
197 + 1000 1 mM —   — 
198 —     —   — 
199 + 650 600 µM – 700 µM —   — 
200 —     —   — 
201 —     —   — 
202 —     —   — 
203 + 300 300 µM —   — 
204 —     —   — 
205 + 600 600 µM —   — 
206 —     —   — 
207 —     —   — 
208 —     —   — 
209 + 800 700µM – 900 µM —   — 
210 —     —   — 
211 +   nonbinder —   — 
212 —     —   — 
213 —     —   — 
214 +   weak binder —   — 
215 —     —   — 
216 —     —   — 
217 —     —   — 
218 —     —   — 
219 + 300 300 µM —   — 
124 
  
220 —     —   — 
221 —     —   — 
222 —     —   — 
223 —     —   — 
224 —     —   — 
225 —     —   — 
226 + 300 300 µM +   — 
227 —     —   — 
228 —     —   — 
229 —     —   — 
230 —     —   — 
231 —     —   — 
232 +   weak binder —   — 
233 —     —   — 
234 —     —   — 
235 —     —   — 
236 + 70 70 µM + 59 + 
237 —     —   — 
238 —     —   — 
239 —     —   — 
240 +   cd, binder + 65 — 
241 —     —   — 
242 —     —   — 
243 +   nonbinder —   — 
244 +   weak binder —   — 
245 —     —   — 
246 —     —   — 
247 —     —   — 
248 —     —   — 
249 —     —   — 
250 —     —   — 
251 +   nonbinder —   — 
252 —     —   — 
253 +   cd, weak binder —   — 
254 —     —   — 
255 —     —   — 
256 +   weak binder —   — 
257 —     —   — 
 
